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Summary 
Transcription Factor IIIC (TFIIIC) is a six-subunit protein complex that recognises highly 
conserved promoter elements within genes transcribed by RNA polymerase III. These 
promoter elements, called ‘A box’ and ‘B box’, are recognised by two subcomplexes of 
TFIIIC, termed ‘τA’ and ‘τB’. The τA subcomplex is formed from three subunits: τ131, 
τ95 and τ55. The τB subcomplex is also composed of three subunits: τ138, τ91 and τ60. 
The binding of TFIIIC to these promoter elements leads to the recruitment of another 
transcription factor, TFIIIB, which subsequently coordinates the recruitment of RNA 
polymerase III to the transcription start site.  
In this thesis, I present my work on the characterisation of a novel interface 
between the τA and τB subcomplexes, which is located between the subunits τ131 and 
τ138. Chemical cross-linking coupled with mass spectrometry provides evidence for an 
important interaction between these two essential proteins, which I have mapped in 
detail using biochemical, biophysical and structural methods. The structure of a highly 
conserved tetra-trico peptide repeat (TPR) domain within τ131 is presented and is 
shown to bind with high affinity to a disordered region of τ138. In addition, I present 
the first high resolution structure of an extended winged helix domain of τ138 that I 
have solved by X-ray crystallography. Finally, I present work detailing efforts to 
produce the TFIIIC complex recombinantly in insect cells. The work presented here will 
further our understanding of the architecture of TFIIIC and provide insight into TFIIIC 
structure and function.  
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Zusammenfassung 
Der Transkriptionsfaktor IIIC (TFIIIC) ist ein Proteinkomplex der aus sechs 
Untereinheiten aufgebaut ist und stark erhaltene Promotorelemente in von RNA 
Polymerase III transkribierten Genen erkennt. Diese als „A box” und „B box” 
bezeichneten Promotorelemente werden durch zwei TFIIIC - Subkomplexe erkannt, die 
„τA” und „τB” genannt werden. Der τA Subkomplex setzt sich aus den Untereinheiten 
τ131, τ95 und τ55 zusammen. Der τB Subkomplex besteht ebenfalls aus drei 
Untereinheiten, τ138, τ91 und τ60. Die Assoziation von TFIIIC an die 
Promotorelemente A Box und B Box durch die τA und τB Subkomplexe leitet die 
Rekrutierung eines weiteren Transkriptionsfaktors, TFIIIB, ein, welcher darauffolgend 
die RNA Polymerase III an den Transkriptionsstartpunkt rekrutiert. 
In dieser Doktorarbeit stelle ich meine Arbeit über die Charakterisierung einer 
neuen Interaktionsstelle zwischen dem τA und τB Subkomplex vor, die zwischen den 
Untereinheiten τ131 und τ138 liegt. Chemische Quervernetzung gekoppelt mit 
Massenspektroskopie beweisen eine wichtige Interaktion zwischen diesen zwei 
essentiellen Proteinen welche ich detailliert mit biochemischen, biophysikalischen und 
strukturbiologischen Methoden charakterisiert habe. Die Struktur einer 
hochkonservierten „tetratricopeptid repeat” Domäne aus dem τ131 Protein, welche an 
eine unstrukturierte Region von τ138 bindet, wird in dieser Arbeit vorgestellt. 
Desweiteren präsentiere ich die erste hochauflösende Struktur einer „extended 
winged helix” Domäne des Proteins τ138 die ich mit Röntgenkristallographie bestimmt 
habe. Abschliessend stelle ich meine Bemühungen zur rekombinanten Produktion von 
TFIIIC in Insektenzellen dar. Die hier gezeigte Arbeit präsentiert neue Erkenntnisse 
über die Struktur und Funktion von TFIIIC und wird unser Verständnis über die 
Architektur dieses Transkriptionsfaktors erweitern.  
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 Introduction    1.
Accessing the genetic information stored within a cell requires the coordinated action 
of many proteins, which often act together as parts of molecular machines [1]. The 
information is stored within the double-stranded and helical DNA molecule [2]. In 
eukaryotes, the DNA is associated with proteins called histones and is packaged within 
the nucleus in the form of chromatin [3]. For this thesis, I have focussed on a protein 
complex called transcription factor (TF) IIIC. This protein must coordinate with a 
molecular machine called RNA polymerase III in order to access specific genetic 
information stored within a eukaryotic cell. 
 
1.1 Transcription initiation and RNA polymerases through evolution 
Transcription, the process whereby DNA is ‘read’ and RNA is subsequently synthesised, 
relies on a highly conserved molecular machine called RNA polymerase. Bacteria and 
archaea utilise only one form of RNA polymerase to read their genomes, whereas 
eukaryotes have divided the task between several [4]. The process of transcription 
consists of three key stages in all three domains of life: initiation, elongation and 
termination. These stages require the concerted action of associated factors, working 
together to ensure the RNA polymerase can progress along the DNA template and 
synthesise an RNA molecule.  
Initiation of transcription requires the formation of a pre-initiation complex (PIC) 
and the subsequent procession from a closed complex to an open complex [5, 6]. In 
brief, key promoter elements are recognised and bound by a transcription factor, 
before DNA is ‘melted’ and then stabilised in the active site of the RNA polymerase. A 
process known as abortive initiation then proceeds [7, 8], whereby short RNA 
transcripts are generated, before a sufficient length is reached and the PIC can escape 
the promoter and RNA synthesis can begin. The next stage in transcription, elongation, 
is not discussed here but has been well reviewed elsewhere [9, 10]. Transcription 
termination will be discussed in a later section.  
There is a high degree of similarity between the catalytic properties of RNA 
polymerase in the three domains of life. This is also true for the mechanisms that lead 
to transcription initiation. However, differences exist between the architecture of the 
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RNA polymerase and the associated transcription factors, which will be discussed 
below.  
 
1.1.1 Bacterial RNA polymerase 
The elucidation of a high-resolution structure of the bacterial RNA polymerase gave 
the first insights into the conserved core of this enzyme family [11]. The ‘crab-claw’ 
shape of the polymerase along with the catalytic centre are preserved through 
evolution, with homologues of the 5 subunits of bacterial RNA polymerase (ββ’αασ) 
present in all three domains of life [12] (Figure 1.1).  
 
 
Figure 1.1 The conserved core of RNA polymerase. (A) The bacterial RNA polymerase is composed of 5 
subunits. (B) The conserved core of bacterial RNA polymerase. (C) The conserved core (blue) is present 
in archaeal and eukaryotic RNA polymerases. Archaea and eukaryotes contain additional subunits, 
including a ‘stalk’ as indicated; see main text and Table 1.1 for details. Figure modified from [12]. 
 
In order for bacterial RNA polymerase to begin transcribing DNA, it must first associate 
with a transcription factor known as a ‘σ-factor’ [13, 14]. These bacterial-specific 
proteins recognise promoter elements known as ‘-10’ and ‘-35’ [6] and enable 
transcription initiation in what is generally an energy-independent event, although 
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examples of σ-factors which require energy from ATP hydrolysis are known [15]. The 
key steps leading to promoter clearance by the RNA polymerase have been well 
reviewed elsewhere [6]. 
 
1.1.2 Archaeal RNA polymerase 
As highlighted in Figure 1.1, archaeal and eukaryotic RNA polymerases contain 
additional subunits. A full list and comparison of these subunits and the associated 
transcription factors between bacteria, archaea and the eukaryote Saccharomyces 
cerevisiae (S. cerevisiae) is summarised in Table 1.1. These additional subunits that are 
present in archaeal and eukaryotic RNA polymerase are essential to the organism, but 
do not seem necessary for RNA synthesis per se [12]. The additional ‘stalk’ subunits, for 
example, are important for other functions such as binding to transcription factors [16, 
17]. 
Archaeal RNA polymerase transcription can be viewed as a ‘mosaic’ of bacterial 
and eukaryotic features [18]. Whilst the structure of the archaeal RNA polymerase [19, 
20] reveals a close similarity to eukaryotic polymerases with regards to additional 
subunits, many features of transcription initiation show more striking similarity to 
bacteria [6, 21]. The most obvious similarity however between archaea and bacteria is 
the possession of only one RNA polymerase.  
 
1.1.3 Eukaryotic RNA polymerases 
The identification of multiple eukaryotic polymerases was first established in work by 
Roeder and Chambon [22, 23]. It is now established that eukaryotes have at least three 
RNA polymerase enzymes, with plants possessing two additional, non-essential RNA 
polymerases [24, 25]. Each RNA polymerase recognises a unique set of promoters and 
is associated with a specific set of transcription factors (reviewed in [26-28]). The best 
characterised of the eukaryotic polymerases is RNA polymerase II, which is principally 
responsible for synthesising messenger RNA (mRNA). The crystal structure of S. 
cerevisiae RNA polymerase II was solved in 2000 [29]. Since then, several more 
structural snapshots of this polymerase with its associated transcription factors and at 
various stages of transcription have been solved [28, 30-33]. Recently, two groups have 
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studied the entire RNA polymerase II PIC using an integrated approach that combined 
crystal structures, cryo-EM reconstructions and cross-linking [34, 35]. 
 
Table 1.1 The conserved RNA polymerase subunits and associated transcription factors 
Bacteria Archaea Eukaryotes 
RNA 
polymerase 
RNA 
polymerase 
RNA  
polymerase II 
RNA  
polymerase I 
RNA 
polymerase III 
RNA polymerase core 
β subunit Rpo1 RPB1 A190 C160 
β subunit Rpo2 RPB2 A135 C128 
α subunit Rpo3 RPB3 AC40 AC40 
α subunit Rpo11 RPB11 AC19 AC19 
  RPB9 A12.2 C11 
 Rpo5 RPB5 RPB5 RPB5 
ω subunit Rpo6 RPB6 RPB6 RPB6 
 Rpo8 RPB8 RPB8 RPB8 
 Rpo10 RPB10 RPB10 RPB10 
 Rpo12 RPB12 RPB12 RPB12 
RNA polymerase stalk 
 Rpo4 RPB4 A14 C17 
 Rpo7 RPB7 A13 C25 
General transcription factors and homologous subcomplexes 
  Tfg1 (TFIIFα) A49 
(N-terminus) 
C37 
  Tfg2 (TFIIFβ) A34.5 C53 
 TFEα Tfa1 (TFIIEα)1  C821 
 TFEβ Tfa2 (TFIIEβ)2 A49 
(C-terminus)2 
C342 
    C31 
 TBP TBP3 TBP5 TBP6 
  TAFs3,4   
 TFB TFIIB Rrn75 Brf16 
1,2Evolutionary relationship remains to be definitively established. 3Part of TFIID (along with TAFs). 4TBP-
associated factors (part of TFIID). 5TBP, Rrn7, Rrn6 and Rrn11 form the core factor. 6TBP, Brf1 and Bdp1 
form TFIIIB. Table and footnotes modified from [12, 36]. 
 
RNA polymerase I contains two additional subunits (A49/34.5) in comparison to RNA 
polymerase II and is responsible for the transcription of the ribosomal RNA precursor 
gene [37]. The presence of additional subunits in RNA polymerase I hinted at 
mechanistic differences with regards to the transcription mechanism. However, the 
solving of the structure of this subcomplex by Geiger and colleagues [38] and its 
location in the context of the RNA polymerase I enzyme (as recently solved by two 
groups [39, 40]) reveals a striking similarity to the general transcription factor TFIIF of 
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RNA polymerase II [41]. These results suggest that RNA polymerase I has incorporated 
this transcription factor as part of its core structure. In fact, further homology is 
observed between these additional subunits and the general transcription factor TFIIE, 
adding weight to the notion that RNA polymerase I and also RNA polymerase III have 
permanently recruited general transcription factors of RNA polymerase II into their 
core structure [4, 36]. 
The 17 subunit RNA polymerase III is the largest of the RNA polymerase 
enzymes and is responsible for transcribing genes encoding for small, untranslated 
RNAs such as transfer RNA (tRNA), 5S ribosomal RNA (5S rRNA) and U6 small nuclear 
RNA (U6 snRNA) (reviewed in [42, 43]). Although a crystal structure for RNA 
polymerase III remains currently unavailable, extensive protein-protein interaction 
networks have been established for the enzyme [44], as well as cross-linking studies 
[45] and a cryo-EM reconstruction at 9.9 Å resolution [46]. As with RNA polymerase I, 
the additional subunits of RNA polymerase III appear to show significant homology to 
the general transcription factors of RNA polymerase II. The subcomplex C37/53 [47, 
48] appears to show homology to TFIIF (and A49/34.5) [36] and can be positioned into 
the cryo-EM density [46] in a similar location as for RNA polymerase II and I [39]. 
Furthermore, a trimeric subcomplex, C82/34/31 [49], shows extensive similarities to 
general transcription factor TFIIE of RNA polymerase II. The structure of the human 
(Homo sapiens or H. sapiens) C82 orthologue (hRPC62) contained a four-tandem 
extended winged helix domain which is structurally homologous to the largest TFIIE 
subunit, TFIIEα (and the archaeal homologue TFE) [50, 51]. The C34 subunit also 
appears to show homology to the TFIIEβ subunit of TFIIE and to the C-terminus of A49 
from RNA polymerase I (see Table 1.1) [36]. 
In summary, eukaryotes have divided the task of transcription between at least 
three RNA polymerases, but appear to have retained some core homologies within 
each enzyme. These homologies extend not only to the catalytic core (which is also 
shared with bacteria and archaea), but also to the additional subunits that exist as 
either permanently or non-permanently recruited factors. This introduction will now 
focus on RNA polymerase III and its associated promoter elements and transcription 
factors.  
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1.2 The promoters of RNA polymerase III 
With the aid of associated transcription factors RNA polymerase III (hereafter referred 
to as Pol III) recognises three types of promoters (reviewed in [42, 43]) (Figure 1.2). 
 
1.2.1 Type 1 promoter 
The sole example from this class is located in the gene for 5S rRNA, which was first 
characterised from Xenopus laevis [52, 53]. An unusual feature of this gene is the 
presence of intragenic promoter elements. The promoter for the 5S rRNA gene 
contains an A box, an intermediate element (IE) and a C box, which together form the 
internal control region (ICR) [54]. The ICR is recognised by the transcription factor 
TFIIIA. This binding then enables the recruitment of TFIIIC, TFIIIB and ultimately Pol III.  
 
1.2.2 Type 2 promoter  
The tRNA genes form the majority of this class, and were initially characterised around 
the same time as the type 1 promoter [55, 56]. As with the type 1 promoters, type 2 
promoters also contain internal promoter elements. These elements, called A box and 
B box, are highly conserved [57] and correspond to the D and T loops of the 
subsequently transcribed tRNA molecule. It should be noted that, whilst the A box of 
type 2 promoters and type 1 promoters are similar and interchangeable [58], they in 
fact recruit different transcription factors: TFIIIA in the case of type 1 promoters and 
TFIIIC in the case of type 2 promoters. A more detailed discussion of the A and B boxes 
of tRNA genes will follow (Section 1.3).  
 
1.2.3 Type 3 promoter 
The type 3 promoters are different with respect to type 1 and type 2 promoters, in 
that their promoter elements are gene external. They were first identified in the U6 
small nuclear RNA (snRNA) genes of mammals [59-61] and the 7SK gene of humans 
[62]. The well characterised human U6 gene contains three important elements, a 
distal sequence element (DSE), a proximal sequence element (PSE) and a TATA box. 
Finally, there are also hybrid forms of Pol III promoters which exist somewhere 
between type 2 and type 3 promoters. The S. cerevisiae U6 snRNA gene for example 
contains a gene-external TATA box but a gene internal A box (as well as a gene external 
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B box). The picture becomes even more complicated when studying 
Schizosaccharomyces pombe (S. pombe) promoters, which reveals that nearly all type 1 
and type 2 promoters contain an additional TATA box which is necessary for 
transcription [63]. 
 
 
Figure 1.2 RNA polymerase III promoters. (A) Type 1 (5S rRNA) promoter. (B) Type 2 (tRNA) promoter. 
(C) H. sapiens type 3 (U6 snRNA) promoter. (D) S. cerevisiae type 3 (U6 snRNA) promoter. Details can be 
found in the main text. Arrows indicate transcription start site. Hs = H. sapiens; Sc = S. cerevisiae; ICR = 
internal control region; IE = intermediate element; A, B and C = respective boxes; DSE = distal sequence 
element; PSE = proximal sequence element; TATA = TATA box; TTTT(TT) = termination signal. Figure 
modified from [42]. 
 
In summary, three classes of promoter are transcribed by Pol III. Each promoter 
contains different elements which all ultimately lead to the same outcome: the 
recruitment of the transcription factor TFIIIB and subsequently Pol III. In type 1 and 
type 2 promoters, TFIIIB must be assembled though interactions with another 
transcription factor (TFIIIA in the case of type 1 and TFIIIC in the case of type 2). In type 
3 promoters, TFIIIB can directly bind the TATA box (and make additional interactions 
with proteins that bind the PSE). These various scenarios have also been summarised 
elsewhere [42, 43]. 
18 
 
1.3 TFIIIC mediated transcription of tRNA genes 
The small genes that encode tRNAs require only two transcription factors in order to 
recruit Pol III. Initially recognised by chromatography of a HeLa cell extract [64], these 
two factors are called transcription factor IIIC (TFIIIC) and transcription factor IIIB 
(TFIIIB). This following section will summarise the currently available information 
regarding TFIIIC and its recognition of A box and B box containing promoters (type 2).  
 
1.3.1 TFIIIC binds the A and B boxes 
The binding of TFIIIC to tRNA genes is mediated through the highly conserved A box 
and B box promoter elements [65, 66]. Consensus sequences for these promoters have 
been defined [57] (Figure 1.3). Mutations of different key bases within the B box 
element have been described and have been shown to abolish TFIIIC binding [67]. The 
A box is located at +12 bases from the transcription start site, a position which appears 
highly conserved. The B box is separated from the A box by a variety of lengths, which 
is dependent on the presence of introns, or differing variable arm lengths within 
different tRNA genes [57]. TFIIIC can accommodate these variations and is assumed 
therefore to harbour a relatively high degree of flexibility [68, 69]. How this flexibility is 
achieved is currently poorly understood. 
The binding of TFIIIC to the B box is a high-affinity interaction (pM-nM) that 
appears to be more critical for TFIIIC-tDNA binding than the A box interaction [70, 71]. 
The A box interaction is weaker (µM) and is inhibited by single-stranded DNA [72]. The 
mechanisms and identities of the crucial domains for TFIIIC-tDNA binding have been 
long sought after. 
 
1.3.2 The molecular architecture of TFIIIC – τA and τB 
In S. cerevisiae, TFIIIC consists of six subunits that form two individual subcomplexes 
called τA and τB, which both harbour DNA binding activity [65, 73] (and reviewed in 
[74]) (Figure 1.3). Proteolysis studies [75] and scanning transmission electron 
microscopy [68] first indicated the existence of these two subcomplexes, which 
resemble a ‘dumb-bell’ shaped molecule of two equal sized components that appear 
to be connected by a ‘flexible linker’. Recent in vivo genome-wide footprinting analyses 
have corroborated that view, again suggesting that the ‘two-lobed’ τA-τB structure sits 
19 
 
over the entire tRNA gene [76]. The τA subcomplex has been shown to bind the A box, 
whilst the τB subcomplex binds the B box [65]. 
 
 
Figure 1.3 The A and B box promoter elements are recognised by TFIIIC. (A) Schematic diagram that 
shows the 6 subunits of TFIIIC (forming the τA and τB subcomplexes) binding to the A and B box 
promoters of a tRNA gene. The termination signal (TTTTTT) is also highlighted. The consensus sequences 
for these promoters are indicated as defined by [57]. R = purine; Y = pyrimidine; n = nucleotide; W = 
weak binding (A or T). (B) Scanning transmission electron microscopy image of TFIIIC bound to tDNA. 
Two densities are visible which correspond to the τA and TB subcomplexes. Figure modified from [68]. 
(C) Footprints of τB and TFIIIC on tDNA. The thick red line indicates the τB footprint, whilst the dashed 
red line indicates the more diffuse τA footprint. Figure modified from [65]. 
 
The τA subcomplex consists of the subunits τ131 (Tfc4), τ95 (Tfc1) and τ55 (Tfc7), 
whilst the τB subcomplex contains τ60 (Tfc8), τ91 (Tfc6) and τ138 (Tfc3) (Figure 1.3). All 
of these subunits are essential for cell viability [77-82]. Their names correspond to 
their approximate molecular weight as assessed by SDS-PAGE, but the names in 
parentheses are also found in the literature. A full list of the subunits with their 
orthologues in S. pombe and H. sapiens is displayed in Table 1.2. Early photo cross-
linking studies have given indications of the positions of these subunits on the tRNA 
gene [83, 84].  
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Table 1.2 TFIIIC subunits and orthologues 
S. cerevisiae S. pombe H. sapiens 
τ131 (Tfc4) Sfc4 TFIIIC102 (γ) 
τ95 (Tfc1) Sfc1 TFIIIC63 (ε) 
τ55 (Tfc7) Sfc7 TFIIIC35 
τ60 (Tfc8) Sfc8 TFIIIC90 (δ) 
τ91 (Tfc6) Sfc6 TFIIIC110 (β) 
τ138 (Tfc3) Sfc3 TFIIIC220 (α) 
Modified from [42]. For H. sapiens, the names in parentheses correspond to pseudonyms in the 
literature. 
 
1.3.3 τ131 
The largest τA subunit, τ131, is predicted to contain many tetra-trico peptide repeats 
(TPRs) [77]. These repeats are protein-protein interaction motifs that are composed of 
34 amino acids that form two antiparallel α-helices [85]. They are often found in large 
protein complexes acting as scaffolds for other subunits [86]. τ131 cross-links 
upstream of the 5’ border of the tRNA gene and is crucial for the assembly of TFIIIB 
(reviewed in [87]). Within human TFIIIC, τ131 has been shown to interact with the τ95 
subunit [88].  
Unpublished work from Nicholas Taylor, a former PhD student in our lab, led to 
the structure determination of a fragment of τ131 containing several N-terminal TPRs. 
Details will be discussed in the Results section.  
 
1.3.4 τ95 and τ55 
The τ95 and τ55 subunits were shown to be located in the proximity of the A box and 
τ95 was subsequently postulated to be the genuine A box-binding subunit [83]. The S. 
pombe τ95 orthologue has subsequently been shown to bind single-stranded and 
double-stranded DNA, though with low affinity and no sequence specificity [89], thus 
consistent with previous findings of A box binding [72]. The crystal structure of the 
DNA-binding domain revealed a winged helix domain with a neighbouring ‘winged 
helix interacting’ domain [89]. τ95 may also indirectly affect B box binding, as a point 
mutant (E447K) was shown to disrupt B box binding [90]. The N-terminus of τ95 forms 
a hetero-dimer with the C-terminus of the τ55 subunit [89]. The structure revealed a 
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strikingly similar fold to the two subunits of the RNA polymerase II transcription factor, 
TFIIF [41, 89]. It is intriguing that Pol III would then possess another copy of this TFIIF-
like fold in addition to C37/53. The τ95-τ55 subcomplex has also been proposed to 
exist independently from the TFIIIC complex [79]. 
In addition to interacting with τ95, τ55 also contains a non-essential and non-
conserved histidine phosphatase domain in S. cerevisiae which may link the activity of 
TFIIIC to metabolic pathways [91].  
 
1.3.5 τ60 and τ91 
τB subunits, τ60 and τ91, both contain WD40 repeats that form canonical seven-bladed 
β-propellers, which pack perpendicularly to form a dimer [92]. τ60 also contains an α/β 
fold which has been shown to bind the TFIIIB subunit, TBP [80, 92]. τ60 is the only 
subunit of TFIIIC that could not be detected in photo cross-linking experiments on 
tRNA genes [84].  
The τ91 subunit could be cross-linked to tRNA genes and is located at the 3’ 
end of the gene near the termination sequence [83]. τ91 has been shown to bind 
single- and double-stranded DNA non-specifically through the disordered region at its 
N-terminus, which contains a so-called ‘AT hook’ [81, 92]. The τ60-τ91 scaffold is 
hypothesised to form a platform for the largest TFIIIC subunit, τ138, which is predicted 
to be the B-box binding subunit [92]. 
 
1.3.6 τ138 
τ138 remains the least well understood and structurally characterised of the TFIIIC 
subunits. Cross-linking of τ138 near the B box [84] provided the first evidence that this 
subunit binds to this important promoter region. In addition, a temperature-sensitive 
point mutant in τ138 (G349E) was identified that reduces the binding of TFIIIC to tRNA 
genes [93]. This residue is completely conserved from yeast to human [94]. 
Furthermore, τ138 is predicted to contain several winged helix domains and high 
mobility group (HMG) boxes, which are both characterised as DNA binding domains in 
other proteins [95]. 
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The precise mechanisms of how τ138 binds the B box are still unknown. τ91 
may play an auxiliary role, as a point mutant (E447K) was shown to suppress the 
effects of the G349E point mutation [81].  
 
1.3.7 Conservation of TFIIIC subunits 
The evolutionary relationship between the six subunits of S. cerevisiae and H. sapiens 
TFIIIC is not immediately obvious in all cases. Human TFIIIC can be separated into two 
fractions by ion exchange chromatography [96, 97]. The first fraction is poorly 
characterised, whilst the second fraction, TFIIIC2, contains the orthologues of all six 
yeast TFIIIC subunits. Sequence conservation is highest with the two τA subunits τ131 
and τ95. The remaining τA subunit, τ55, was the last human TFIIIC subunit to be 
characterised [98] and was revealed not to contain the histidine phosphatase domain 
described earlier.  
Conservation of the τB subunits is much weaker and it is largely through the 
efforts of cloning and characterising S. pombe orthologues that a relationship between 
S. cerevisiae and H. sapiens τB subunits could be established [94, 99]. The human τ60 
and τ91 orthologues, TFIIIC90 and TFIIIC110, have been shown to possess histone 
acetlytransferase activity [100, 101], implicating a role in chromatin modification. 
These adaptations, which are not apparent in yeast orthologues, may explain the 
significant divergence in sequence. The τ138 subunit shows the least conservation 
amongst the TFIIIC subunits. Proteolysis experiments revealed that the human TFIIIC 
subunit, TFIIIC220 (α), contains an 83 kDa DNA binding domain that recognises the B 
box [102] indicating that this is the τ138 orthologue in human, despite the sequences 
being poorly conserved. Later bioinformatics analysis concluded there is similarity 
within the N-terminal third of τ138 orthologues [103].  
In summary, τ131 shows the highest overall conservation over the entirety of 
its sequence, possibly due to its essential role in TFIIIB recruitment (Section 1.4.1). 
τ138, in contrast, shows very weak conservation despite its hypothesised role in 
binding the critical B box promoter.  
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1.3.8 The identity of the flexible linker in TFIIIC 
An important open question concerns which subunits are involved in forming the 
‘flexible linker’, which allows TFIIIC to recognise differently spanned promoter regions 
using its flexibility between the presumably rigid τA and τB subcomplexes (Section 
1.3.2). Both τ60 and τ95 have been postulated as potential candidates [80, 90]. τ60 has 
been suggested owing to its role in binding TBP and the fact that it does not cross-link 
to DNA. The human orthologue has also been shown to bind human orthologues of 
τ131 and τ95 [101]. τ95 is proposed as it has been shown to bind τ91 and τ138 by co-
immunoprecipitation experiments [90]. Finally, whilst screening for suppressors of the 
temperature-sensitive G349E mutation of τ138, Rozenfeld and Thuriaux isolated 
several mutations within the TPR-containing region of τ131 [104]. This genetic 
interaction between τ131 and τ138 has not been directly demonstrated or investigated 
biochemically.  
The precise identity and nature of the linker remains an open question and no 
direct interaction between τA and τB has been demonstrated yet using purified 
proteins to the authors’ knowledge.  
 
1.4 The recruitment of TFIIIB and Pol III to tRNA genes 
With TFIIIC bound to the A box and B box promoters of the tRNA gene, TFIIIB can then 
be assembled. TFIIIB is composed of three proteins: Brf1, Bdp1 and TBP (reviewed in 
[42, 43]). TBP can direct the recruitment of TFIIIB to TATA-containing type 3 
promoters. However, in the case of type 1 and type 2 promoters, the additional 
‘assembly’ factors TFIIIA and TFIIIC are required, respectively. TBP is a protein shared 
by all three RNA polymerase systems [105], whilst Brf1 and Bdp1 are specialised for 
the Pol III transcription system and can be cross-linked to DNA [106]. Brf1 shows 
sequence and structural homology to the general transcription factor TFIIB, whilst 
Bdp1 shows no homology to any other known transcription factor.  
 
1.4.1 TFIIIC recruits and assembles TFIIIB onto type 2 promoters 
As previously described, τ60 and τ131 have been shown to interact with TFIIIB 
subunits. τ60 interacts with TBP and τ131 is thought to be the primary TFIIIC subunit 
responsible for the assembly of TFIIIB on type 2 promoters. The role of τ131 in TFIIIB 
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assembly has been extensively studied and a pathway for TFIIIB recruitment has been 
proposed (reviewed in [87]). Yeast two-hybrid analysis initially revealed that the TBP 
and Brf1 proteins interact and that Brf1 makes additional contacts with τ131 [107]. 
Subsequently, various biochemical and biophysical techniques have been used to map 
the binding of Brf1 and Bdp1 to a conserved N-terminal TPR array in τ131 [108-114]. 
Mutational analysis and biochemical mapping have led to the conclusion that Brf1 and 
Bdp1 compete for TPR binding sites within τ131 [109]. In vivo, it is thought that Brf1 
must first be bound to TFIIIC (along with TBP) before Bdp1 can bind. The C-terminal 
half of Brf1 provides a binding platform for TBP and Bdp1 [115]. The binding of Bdp1 
leads to a stable TFIIIB-TFIIIC-DNA complex [116] that can initiate transcription with Pol 
III. This step-by-step recruitment of TFIIIB components presumably requires flexibility 
within τ131 and/or TFIIIB [117]. 
 
1.4.2 Pol III recruitment and transcription initiation 
Yeast two-hybrid studies, biochemical pull-downs and photo cross-linking have all 
contributed to elucidating the network of interactions that occurs between TFIIIC, 
TFIIIB and Pol III (Figure 1.4). With TFIIIB assembled on the type 2 promoter, the 
polymerase can be recruited and PIC formation can be completed. The C37/53 Pol III 
dimer appears to play a central role in connecting components of the PIC, with C37 
shown to interact with Bdp1 and C53 interacting with τ131 [118]. Brf1 has been shown 
to interact with the Pol III subunit C17 [17] as well as with C34, C160 and C128 [115] 
via sites in its TFIIB-like N-terminus. τ131 has also been shown to interact with ABC10α 
[119]. In yeast, τ131 appears to be the only TFIIIC subunit which interacts with Pol III 
and thus may play a crucial role in its recruitment to type 2 promoters, again 
explaining its high conservation. It should be noted that in humans however, other 
TFIIIC subunits have been shown to interact with Pol III (reviewed in [42]).  
 A time-resolved ‘movie’ of how these interactions occur in the context of PIC 
assembly is still unresolved. However, although TFIIIB is still considered the initiation 
factor for ‘proper’ Pol III transcription [120], TFIIIC may still be important for directing 
Pol III accurately to transcription start sites through interactions with τ131.  
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Figure 1.4 Known interactions within the S. cerevisiae PIC. Lines indicate interactions that have been 
determined by yeast two-hybrid, pull-downs or photo cross-linking experiments. See text for details and 
references.  
 
1.4.3 Transcription termination and recycling 
The mechanisms of transcription termination in Pol III are poorly understood, despite 
the apparent simplicity of the termination signal. The termination signal is a run of 
consecutive thymine residues in the non-template strand, the length of which is 
species dependent [121]. The process of termination has been described as consisting 
of two phases. Firstly, a pausing step upon the encountering of the poly-thymine 
stretch by Pol III and secondly a release step of the RNA [122]. A very recent study has 
also demonstrated the requirement for hairpin formation within the synthesised RNA 
to ensure termination [123]. Pol III subunits C53 and C37 have been implicated in the 
process of termination [48] as well as the TFIIIC subunit τ91, which cross-links to the 
termination signal [84].  
One fascinating aspect of Pol III transcription is the predicted mechanism of 
facilitated recycling [124, 125]. This pathway allows the terminating Pol III to be 
efficiently re-recruited to the transcription start site and initiate a second round of 
transcription. The precise details of the pathway remain unclear [125] but several 
proteins (such as PC4, NF1 and DNA topoisomerase I) have been implicated in the 
stimulation of this process [126, 127]. Interestingly, the presence of TFIIIB alone 
appears sufficient to direct re-initiation of transcription, with TFIIIC only required for 
recycling at longer genes [128].  
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The ‘dispensability’ of TFIIIC for re-initiation and the paradox that TFIIIC sits over the 
entire gene that Pol III must transcribe (and so ultimately acts as a barrier to 
transcription), raises the question of the role of TFIIIC after PIC establishment. These 
topics, amongst others, are discussed in the next section.  
 
1.5 TFIIIC within the genome 
1.5.1 Genome occupancy of TFIIIC during transcription 
It has been estimated that 70-85% of the nucleotides present in a cell are designated 
for the production of tRNAs, rRNAs, and mRNAs that encode ribosomal proteins [129]. 
As a consequence, these processes must be regulated to ensure the cell does not use 
up vast amounts of resources and energy unnecessarily. Interestingly, tRNA genes and 
5S rRNA genes are co-localised in specific areas of the nucleus, suggesting a 
coordinated regulation [130].  
When the cell faces a situation of favourable growth conditions (i.e. sufficient 
nutrients) transcription rates increase, when the situation is less favourable the 
transcription rate decreases. This scenario has been examined genome-wide with 
regards to the occupancy of TFIIIC [131]. In a study by Roberts and colleagues, it was 
observed that Pol III occupancy dramatically reduced on selected tRNA genes upon 
repression of nutrient availability. Strikingly, TFIIIC occupancy greatly increased, 
whereas TFIIIB occupancy remained constant. Reversion to conditions of plentiful 
nutrients increased Pol III occupancy and caused a decrease in the presence of bound 
TFIIIC at these genes. These observations link back to the questions raised in Section 
1.4.3: what happens to TFIIIC during transcription elongation? It is assumed that TFIIIC 
must be released from the actively transcribed gene, in order for Pol III to gain access 
to the template strand. This idea is supported by another study which also showed far 
lower occupancy of TFIIIC at actively transcribing genes when compared to Pol III and 
TFIIIB [132].   
The precise molecular mechanisms that are involved at actively transcribed Pol 
III loci throughout the genome remain elusive. Although evident that TFIIIC is essential 
for initially assembling TFIIIB and the formation of a PIC, the subsequent requirements 
for this factor in elongation, termination and re-initiation remain unresolved.  
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1.5.2 The non-transcriptional roles of TFIIIC 
The non-transcriptional roles of TFIIIC, its association with chromatin and binding 
occupancy over the genome have recently gained particular attention and have been 
well summarised elsewhere [66, 133, 134]. This research was initiated by the 
identification of isolated B box elements in the genome of S. cerevisiae [135]. It was a 
surprise to observe that these canonical B box elements were associated with TFIIIC 
but not with TFIIIB or Pol III. These sites were later identified in S. pombe [136] and 
have since been termed ‘extra TFIIIC’ (ETC) sites. It was observed that one ETC site is 
situated in the promoter region of TFC6, a gene encoding the τ91 subunit of TFIIIC 
itself, and that TFIIIC binding leads to a decrease in transcription of this gene [137]. 
This hints at a cross-talk between the RNA polymerase II and Pol III transcription 
apparatuses, but many other non-transcriptional roles have been attributed to TFIIIC 
as well (Figure 1.5) [133].  
 
 
Figure 1.5 TFIIIC as a platform for chromatin processes. Figure modified from [133]. 
 
The binding of TFIIIC to tRNA genes, through isolated or Pol III-associated B boxes, may 
act as a boundary to heterochromatin spreading and act to organise genome 
architecture (reviewed in [133, 138]). In addition, the association of TFIIIC with 
condensin, a protein crucial for the maintenance of chromosome architecture, has 
been implicated in these processes (reviewed in [139]). Work carried out in S. 
cerevisiae and S. pombe has demonstrated co-localisation of condensin with TFIIIC at 
both Pol III-transcribed B boxes and ETC B boxes [140, 141]. Furthermore, a mutation 
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in the τ138 subunit (the temperature-sensitive G349E introduced in Section 1.3.6) 
rescues a mutation in condensin that causes a decrease in association of tRNA genes 
with centromeres [141]. The interplay of condensin and TFIIIC may thus be important 
for maintaining accurate chromatin architecture in the nucleus of eukaryotic cells.  
 
1.6 Scope of this thesis 
I have outlined our current knowledge and understanding concerning the structure 
and function of the TFIIIC complex. High-resolution structural information of TFIIIC sub-
domains has been obtained and there are accumulating insights into the positioning of 
individual subunits on DNA and the recruitment cascade of TFIIIB and Pol III.  
There are however key questions that remain: 
- What is the identity of the linker between the τA and τB subcomplexes? 
- Which domain or domains bind the B box of type 2 promoters? 
- What is the overall molecular architecture of TFIIIC? 
During the course of my PhD I attempted to address these questions by using a variety 
of biochemical, biophysical and structural techniques. Here I present mass-
spectrometry coupled cross-linking analyses of the entire TFIIIC complex and identify 
and characterise the first link between a τA and a τB subunit. I also present the first 
high resolution structure of a τ138 domain and investigate the identity of the B box 
binding domain. Finally, I also present my work on producing TFIIIC recombinantly in 
insect cells. 
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 Results - Linking τA and τB 2.
This chapter describes the biochemical and structural characterisation of a link 
between the two largest subunits of TFIIIC, namely τ131 in the τA subcomplex and 
τ138 in the τB subcomplex. The current working hypothesis in the field is based on a 
‘flexible linker’ between the τA and τB subcomplexes, that involves one or more TFIIIC 
subunits. 
 In our lab, the crystal structure of τ131 (123-566), hereafter referred to as the 
‘TPR array’ had been solved to 3.4 Å resolution by a former PhD student, Nicholas 
Taylor . Here, I present experiments which reveal that this domain is involved in a link 
with the τB subunit τ138. I will show the precise mapping of the interaction by GST 
pull-down assay, isothermal titration calorimetry (ITC), cross-linking and mutational 
analysis. Unexpectedly, the mapped interaction site within the TPR array of τ131 
overlaps with previously characterised binding sites for TFIIIB. 
 
2.1 TFIIIC cross-linking 
As a first step in identifying TFIIIC subunits that may bridge the gap between the τA 
and τB subcomplexes, I carried out chemical cross-linking of endogenously purified 
TFIIIC (coupled with mass spectrometry) in collaboration with the Beck group at EMBL 
Heidelberg.  
 
 
Figure 2.1 TFIIIC can be purified from S. cerevisiae. (A) Schematic diagram of TFIIIC. (B) Schematic 
diagram of the TAP-tag at the C-terminus of the τ60 gene. CBP = calmodulin binding peptide; Prot A = 
protein A; TEV = Tobacco Etch Virus. (C) Main purification steps. Details can be found in the Appendix.  
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2.1.1 Purification of endogenous TFIIIC from S. cerevisiae 
TFIIIC was purified from S. cerevisiae by means of a tandem affinity purification (TAP) 
tag at the C-terminus of τ60. The initially established protocol was modified and 
optimised by Nicholas Taylor and myself. Figure 2.1 summarises the purification 
strategy, with further details available in the Appendix. In preparation for lysine-lysine 
cross-linking, the sample eluted from the final purification step is buffer exchanged 
into HEPES buffer (pH 7.5) using an analytical Superose 6 10/300 gel filtration column 
(GE Healthcare). This step was necessary to ensure that no Tris is present in the buffer, 
as the amine groups of Tris molecules can compete for cross-linking and thus quench 
the reaction. The analytical gel filtration step also serves as a quality control step for 
the integrity and purity of the preparation (Figure 2.2). 
 
 
 
Figure 2.2 Endogenous TFIIIC can be purified to homogeneity. (A) The samples were injected onto a 
Superose 6 10/300 column (GE Healthcare) and elution position was analysed. Positions of known 
molecular weight standards are indicated at 670 kDa and 158 kDa. (B) 12% SDS-PAGE of gel filtration 
peak. * = τ91 degradation product, confirmed by mass spectrometry; CBP = calmodulin binding peptide; 
MW = molecular weight; kDa = kiloDalton.  
 
2.1.2 Chemical cross-linking of purified TFIIIC 
The principles behind chemical cross-linking coupled with mass spectrometry have 
been well reviewed [142]. In short, native protein complexes are incubated with a 
cross-linking reagent that can covalently link primary amines that are present on the 
surface of a protein complex. These primary amines, which occur in lysine side chains 
and the N-termini of proteins, will be cross-linked if they occur within the length of the 
cross-linking reagent. After digestion of the cross-linked protein complex by proteases, 
cross-linked peptides can be identified using mass spectrometry, thus providing 
restraints that can give information on the architecture of subunits within a protein 
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complex. In collaboration with the Beck group, we used state of the art liquid 
chromatography (LC)-coupled tandem mass spectrometry (MS/MS) with chemical 
cross-linking in order to obtain a map of distance restraints for TFIIIC that could 
indicate binding interfaces.  
A detailed protocol of the cross-linking method can be found in Materials and 
Methods, 6.1.2. Briefly, 30 μg (1 μg/μl) of purified TFIIIC was cross-linked by addition of 
an iso-stoichiometric mixture of H12/D12 isotope-coded, di-succinimidyl-suberate 
(DSS, Creative Molecules). Equal amounts of cross-linker were added ten times every 4 
min to a final concentration of 2 mM. The reactions were then quenched and digested, 
before cross-linked peptides were enriched using size-exclusion chromatography [143]. 
The use of an isotope-labelled cross-linker aids mass spectrometry identification in the 
next step, as modified peptides occur as isotope pairs on the MS1 level. LC-MS/MS was 
employed for analysis of the cross-linked samples, with a final list of identified peptides 
filtered by the following criteria: false discovery rate (FDR) = 0.05, minimum delta 
score = 0.95, MS1 tolerance window of 4 to 7 ppm, linear discriminant (ld)-score > 25 
(Figure 2.3 and Appendix). An ld score of over 25 was chosen to reduce false-positives, 
and was based on analysis of test cases where obtained cross-links were mapped onto 
an already solved crystal structure (Jan Kosinski, personal communication).  
 
2.1.3 Cross-linking reveals a link between subunits τ131 and τ138 
We identified 121 unique cross-links (33 inter-subunit/88 intra-subunit) for TFIIIC that 
provide interesting new insights into various aspects of TFIIIC architecture. For this 
chapter, I will focus on the interface observed between τ131 and τ138. In this region a 
dense network of cross-links extend from the TPR array at the N-terminus of τ131 to a 
central region of τ138 (Figure 2.3). With the exception of τ95, this region represents 
the only link between a τA and a τB subunit identified by cross-linking. Importantly, the 
cross-links occurred within the TPR array of τ131, a domain of which we already had a 
structure, which provided a detailed framework in which to investigate the interaction 
in detail. 
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2.2 Mapping the τ131 – τ138 interaction  
The structure of the TPR array of τ131 is shown in Figure 2.4. The TPR array is highly 
conserved, as can be seen from the schematic structure predictions of τ131 
orthologues in S. pombe and H. sapiens. τ131 is predicted to contain many TPR 
repeats, in addition to the ones within the TPR array at the N-terminus. A survey of 
different structure prediction servers suggests that up to 7 extra TPRs might exist 
within the C-terminal half of the protein. That the cross-links obtained occurred 
between the TPR array and a largely disordered region of τ138 is not so surprising, as 
TPR-containing proteins often stabilise extended, disordered regions within protein 
complexes [85].  
 
Figure 2.4 Overview of the tetra-trico-peptide repeat (TPR) domains found in τ131 orthologues from S. 
cerevisiae, S. pombe and H. sapiens. The TPR array is shown in ribbon representation and is coloured 
according to the scheme displayed. Putative additional TPRs are coloured grey. Ext. = extended. 
 
Figure 2.5 shows predicted structural motifs found within τ138 and orthologues in S. 
pombe and H. sapiens. Bioinformatic predictions revealed the presence of three 
winged helix domains at the N-terminus of the protein, one or two at the C-terminus 
and one central winged helix, immediately adjacent to the cross-links. Winged helix 
domains are usually implicated in binding DNA, but have also been characterised as 
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protein-protein interaction domains [95]. I therefore set out to identify the minimal 
region in τ138 required for interaction with τ131, focussing on constructs which 
included the predicted central winged helix. 
 
 
Figure 2.5 Overview of the winged helix (WH) domains predicted to be found in τ138 orthologues from 
S. cerevisiae, S. pombe and H. sapiens. The central winged helix and the additional region investigated 
are highlighted in dark green and light green, respectively. Dashed lines in TFIIIC220 indicate a non-
conserved region which is removed here for simplicity. 
 
2.2.1 Biochemically mapping a critical τ131- τ138 interaction region 
To map which part of the central τ138 region interacts with the TPR array of τ131, I 
performed a Glutathione S-Transferase (GST) pull-down assay. I purified the TPR array 
for these studies according to established protocols. Based on the obtained cross-links, 
I designed and cloned various τ138 fragments as GST-fusions. I used the pETM30 
vector, which introduces an N-terminal, Tobacco Etch Virus (TEV) protease-cleavable, 
6x-histidine-GST affinity tag. The GST-fusions were expressed and purified as detailed 
in Materials and Methods, 6.1.4.  
The results of the GST pull-down assay are shown in Figure 2.6. Constructs that 
included the winged helix up to residue 693 and a construct that just represented the 
disordered region up to this residue (641-693) showed a stoichiometric interaction 
with the τ131 TPR array, but the winged helix (WH) alone did not pull-down the τ131 
TPR array. Extending the winged helix to residue 681 did reveal an interaction with 
τ131, but it appeared sub-stoichiometric. A construct including only the disordered 
region up to this residue (641-681) also showed a very weak, sub-stoichiometric 
interaction. A negative control of GST alone was included to control for interaction of 
the τ131 TPR array with GST. The first lane in the ‘Pull Down’ gel shows that τ131 does 
not interact with GST.  
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The results from this assay suggested that the region 641-693 (hereafter referred to as 
τIR – τ131-Interacting Region) of τ138 is necessary and sufficient to form a stable, 
stoichiometric interaction with the TPR array of τ131.  
 
 
Figure 2.6 GST pull-down assay confirms a τ131-τ138 interaction. GST pull-down assay of recombinant 
GST-τ138 protein and GST with untagged τ131 TPR array. 12% SDS-PAGE of pull-down (top) and input 
(bottom) samples are shown. WH = winged helix (546-641). * = degradation products of τ138. 
 
2.2.2 Biophysically mapping a critical τ131- τ138 interaction region 
ITC was used to confirm the interaction site mapped with GST pull-down and to obtain 
precise binding affinities of the interacting fragments in the absence of affinity tags. 
ITC was carried out in collaboration with Vladimir Rybin, Biophysical Support Scientist 
at EMBL Heidelberg. I purified ‘WH’, ‘WH-681’ and ‘WH-693’ as before, but this time 
cleaving the GST tag with TEV protease and using gel filtration to purify pure, cleaved 
proteins (data not shown). As the constructs ‘641-681’ and ‘641-693’ were short and 
predicted to be disordered, I carried out a different purification protocol that is 
detailed in Materials and Methods, 6.1.5. In this protocol, the proteins were purified 
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by the 6x-histidine tag (rather than the GST tag), using nickel-NTA agarose resin 
(Qiagen). After TEV protease cleavage, the cleaved proteins were passed through a 
second nickel column that bound the TEV protease and un-cleaved protein, but 
allowed cleaved protein to pass in the flow-through (Figure 2.7A). I then used a MonoS 
cation exchange column for a final purification round (Figure 2.7B). The proteins were 
checked for aggregation on a Superdex Peptide 10/300 GL analytical gel filtration 
column (GE Healthcare) (data not shown). Despite being predicted as generally 
unstructured (Figure 2.7C), these proteins were not observed to form aggregates and 
so were suitable for ITC measurement.  
 
 
 
Figure 2.7 The τ138 ‘τIR’ (641-693): Purification and sequence conservation. (A) 18% SDS-PAGE of the 
TEV protease cleavage of GST-τ138 τIR. M = marker; T = TEV protease; FT = flow-through. (B) Elution 
fractions from MonoS column. (C) Alignment of S. cerevisiae and S. pombe ‘τIR’ sequences. Identical 
residues are boxed in brick red. Highly conserved residues are boxed in purple. The secondary structure 
prediction is highlighted above the alignment. Cylinders denote α-helices; arrows denote β-strands. 
 
The construct containing the winged helix with the τIR region binds to the τ131 TPR 
array with a Kd of 100 nM (Figure 2.8A). A similar value (80 nM) is obtained for the τIR 
alone (Figure 2.8B). A construct containing the winged helix extended to residue 681 
still showed binding, but at a weaker affinity of 2.6 µM (Figure 2.8C). The construct 
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encompassing residues 641-681 showed no binding (data not shown). Finally, the 
winged helix alone showed no binding to the τ131 TPR array by ITC (Figure 2.8D). 
In summary, the findings from ITC experiments are consistent with those from 
the GST pull-down assay: the τIR is necessary and sufficient for binding the τ131 TPR 
array with nanomolar affinity.  
 
 
Figure 2.8 Determining binding affinities for the τ131-τ138 interaction using ITC. (A-D) See text for 
explanation. N = binding stoichiometry between τ131 and τ138; Kd = dissociation constant.  
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2.3 Crystallisation attempts of a τ131 TPR array - τ138 τIR complex 
Having defined a minimal region of τ138 that interacted with τ131 and intrigued by 
how this disordered region is stabilised by the TPR array, I next set out to purify a 
complex of these two regions in order to crystallise the complex and solve its 
structure.  
 
2.3.1 Purifying the τ131 - τ138 complex 
The reader is referred to Materials and Methods for full details of cloning, expression 
and purification protocols. Vectors encoding the sequences for the τ131 TPR array and 
τ138 τIR were co-expressed in p*RARE Escherichia coli (E. coli) cells. The complex was 
purified by means of an N-terminal, TEV protease-cleavable, GST affinity tag present 
on the τ138 subunit. Figure 2.9A shows the elution peak of the τ131-τ138-GST 
complex. As can be easily appreciated, a large amount of material could be obtained 
(~200 mg from 12 L of E. coli). The complex was incubated with GST-tagged TEV 
protease to remove the GST tag and the flow-through was collected. Figure 2.9B shows 
the result of the TEV protease cleavage, indicating the successful collection of a τ131-
τ138 cleaved complex in the flow-through.  
 
 
Figure 2.9 GST-purification of the τ131 TPR array - τ138 τIR complex. (A) 12% SDS-PAGE showing elution 
fractions from a GST-affinity column. (B) 18% SDS-PAGE showing TEV protease cleavage of the τ131-τ138 
complex. M = marker; T = TEV protease; FT = flow-through; E = 2nd elution of free GST and GST-TEV 
protease 
 
At this stage, it was apparent that this purification strategy resulted in a large yield of a 
highly pure sample. The complex was injected onto a Superdex 200 preparative gel 
filtration column (GE Healthcare) and eluted as a single species (Figure 2.10A). The 
elution volume corresponds to a higher molecular weight than a monomer (~57 kDa); 
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this is probably due to the extended shape of the TPR array and was also observed for 
the apo-τ131 TPR array. The complex was evaluated by SDS-PAGE (Figure 2.10B) and 
judged to be appropriate for crystallisation trials, as it was highly pure and showed a 
stoichiometric relationship between τ131 and τ138. 
 
 
Figure 2.10 The τ131 TPR array - τ138 τIR complex can be purified to homogeneity. (A) Analytical gel 
filtration profile of the τ131-τ138 complex. The sample was injected onto a Superdex 200 10/300 GL 
column (GE Healthcare) and elution position analysed. Positions of known molecular weight standards 
are indicated at 158 kDa and 44 kDa. (B) 18% SDS-PAGE of a preparative S200 gel filtration peak. M = 
marker.  
 
2.3.2 Crystallisation of the τ131 - τ138 complex 
The complex was concentrated to 60 mg/mL for initial crystallisation trials. Crystals 
were grown at 20°C using the sitting drop method in an initial broad screening 
approach. Initial crystals were obtained in the JCSG screen (Molecular Dimensions) 
with a reservoir solution of 0.2 M MgCl2, 0.1 M Tris pH 8.5 and 50% ethylene glycol as 
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the precipitant (Figure 2.11A). Manual refinement screens were set up around this 
condition with the best hits (i.e. single, well-defined crystals) occurring in 0.2 M MgCl2, 
0.1 M Tris pH 8.3 and 42.5% ethylene glycol. The high percentage of ethylene glycol in 
the condition meant that the crystals were already cryo-protected and therefore could 
be flash-frozen immediately in liquid nitrogen. One observation at this stage was that 
there was a large amount of quite thick skin or precipitate formed around some of the 
crystals although it was not clear whether this was protein or a component of the 
crystallisation cocktail. It was removed from the crystals for data collection (see 
Discussion). 
 
 
Figure 2.11 Crystallisation and diffraction of the τ131-τ138 complex. (A) Typical crystal obtained for the 
τ131-τ138 complex. (B) Collected crystal in a loop for data collection. (C) Example of a diffraction image 
taken for the crystal fished in (B). 
 
2.3.3 X-ray diffraction from τ131 - τ138 complex crystals 
Crystals were collected for native data collection, as it was hoped that a molecular 
replacement solution would be found using the apo-τ131 TPR array structure. Figure 
2.11B and Figure 2.11C show a typical collected crystal and diffraction image. Initial 
processing using XDS [144] suggested that the space group for these crystals was P62 
(see Materials and Methods, 6.4 for further details on data processing). This was 
different to that of the apo-τ131 TPR array (P43). It was apparent from early on that 
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resolution would be a limiting factor for these crystals. Thus, in order to increase the 
signal to noise ratio for higher resolution reflections, a highly redundant data set (7200 
images, 0.1° rotation) was collected. The crystals did not display signs of radiation 
damage up to this point. The details of the collected data are summarised in Table 2.1. 
The best dataset obtained extended to 3.3 Å resolution.  
 
Table 2.1 τ131 (123-566) Data collection and refinement statistics 
 
 τ131 (123-566)  
Native 
 τ131 (123-566)  
SeMet 
Data collection1    
Beamline P14 (PETRAIII)  ID23-1 (ESRF) 
Space group P62  P62 
Cell dimensions 
    a, b, c (Å) 
116.08, 116.08, 95.75 
 
 121.71, 121.71, 97.78 
 
    
Wavelength (Å) 0.97626  0.97924 
Resolution (Å)  50-3.29 (3.37-3.29)   50-4.50 (4.61-4.50) 
CC 50 1.0 (0.56)  1.0 (0.47) 
Rmerge (%) 6.7 (164.0)  9.6 (183.3) 
I/σI 37.62 (2.13)  16.65 (1.62) 
Completeness (%) 99.7 (97.0)  99.1 (89.9) 
Redundancy 38.1 (23.6)  20.3 (16.6) 
Sites -  8 SeMet 
 
Refinement 
   
Resolution (Å) 44.5 – 3.29   
No. reflections 11247   
Rwork/ Rfree (%) 29.6/31.7   
 
No. atoms 
   
    Protein 3491   
 
B-factors (Å2) 
   
    Protein 138.36   
    
R.m.s deviations    
    Bond lengths (Å)  0.003   
    Bond angles (°) 0.715   
1 Values in parentheses correspond to the highest-resolution shell 
 
 
2.3.4 Solving the structure of the τ131 - τ138 complex  
The structure was solved by molecular replacement using Phaser [145] but only after 
fairly extensive modification of the τ131-apo search model. In particular, the extreme 
N-terminal and C-terminal TPRs and the extended helix (Figure 2.4) had to be 
truncated, indicating variability in these regions of the protein within these crystals. 
After iterative rounds of model building and refinement using Coot [146] and the 
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Phenix package [147] the model was refined to a Rwork/ Rfree of 29.6%/31.7% with good 
stereochemistry (Table 2.1). However, no additional density which would be indicative 
of the τ138 protein was visible, and the reasons for why this might be will be discussed 
later (Section 2.6.1). A simulated-annealing composite omit map of the TPR array from 
the 3.3 Å dataset is shown in Figure 2.12A. In general, the map is of good quality. In 
less flexible regions, in the helices of the TPRs, side-chains could be placed with 
confidence (Figure 2.12B). The situation for more flexible regions such as at the N- and 
C-termini and the loops between some of the TPR helices was quite different. Here, 
owing to high temperature factors (Figure 2.14B) the electron density was harder to 
interpret, with many side-chains showing no clear density. 
 
 
Figure 2.12 Electron density of the 3.3 Å dataset of the TPR array. (A) Simulated-annealing composite 
omit map of the TPR array form the 3.3 Å native dataset contoured at 1σ. (B) Close-up view of a 
simulated-annealing omit map (blue) of the ‘A’ helix of TPR 4 (grey) with side-chains labelled (oxygen 
atoms, red; nitrogen atoms, blue; sulphur atoms, yellow). Map contoured at 1σ.  
 
2.3.5 Selenomethionine incorporation into τ131 - τ138 complex crystals 
As an additional validation that the τ131 structure was correct, crystals of a 
selenomethionine (SeMet) derivative of the τ131-τ138 complex were grown. The 
complex was expressed and purified as for the native complex, albeit with 
modifications at the expression stage to ensure that methionine residues were 
substituted for SeMets (see Materials and Methods, 6.1.9, for details). Mass 
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spectrometry was used to confirm the incorporation of SeMet into the protein. The 
complex was concentrated to 30 mg/mL for crystallisation trials. Crystals were grown 
at 20°C by the hanging drop method using refinement screens already established for 
the native complex. Crystals grew in 0.2 M MgCl2, 0.1 M Tris pH 8.2-8.5 and 42.5% - 
45% Ethylene Glycol. Only a few crystals were obtained in comparison with the native 
complex and they were significantly smaller. The morphology was the same.  
A dataset of 3600 images at 0.2° rotation was collected and the statistics of the 
collected data are displayed in Table 2.1. The overall resolution extended to 4.5 Å but 
more importantly anomalous signal from the selenium atoms was recorded to ~5.8 Å. 
The structure was solved by single-wavelength anomalous diffraction (SAD) combined 
with density modification using the program autoSHARP [148], with the program able 
to locate the positions of 8 SeMet sites. This is consistent with 7 methionine residues 
and 1 additional cloning artefact at the N-terminus. Upon inspection of the electron 
density, 6 of the 7 selenium peaks overlapped with built methionine residues (see the 
legend of Figure 2.13). In conclusion, a SeMet dataset confirmed the validity of our 
molecular replacement solution and indicated that the model had been built correctly. 
However, again there was no electron density for the τ138 τIR. 
 
 
Figure 2.13 Selenium peaks indicate the positions of methionine residues in the T131 TPR array. (A) 
Anomalous difference Fourier map (red) showing selenium positions contoured at 5σ. Peak 1 is most 
likely the N-terminal methionine residue from cloning as it does not overlap with a built methionine 
residue. A peak between TPR 7 and TPR 8 ‘?’ occurs in a region of no methionine residues and could 
possibly come from a flexible N-terminal methionine in a symmetry mate (the size of the peak is much 
smaller in comparison to the others). No selenium peak was observed at M337, probably owing to the 
high degree of flexibility in this region. (B) Close-up of boxed region from A. Methionine residue are 
labelled as sticks and numbered accordingly.  
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2.3.6 Comparing the P43 and P62 τ131 TPR array structures.  
The P62 structure of the τ131 TPR array is highly similar to that of the P43 structure 
solved originally (RMSD Cα-380 = 1.83 Å) (Figure 2.14A). Additional residues are visible 
at the N and C termini of the P62 structure and the TPRs at the N and C termini are 
shifted when compared to the P43 structure. These regions are also where the most 
flexibility occurs within the structure (as indicated by the temperature factors 
displayed in Figure 2.14B). In general, the structures are in good agreement, thereby 
showing that even in two different crystallographic environments and lattices the TPR 
repeats are arranged in an almost identical shape.  
 
 
Figure 2.14 Flexibility within the TPR array.  (A) Overlay of the P62 TPR array (red) and the P43 structure 
solved previously (lilac). Arrows indicate regions of greatest difference. (B) Temperature factors of the 
P62 structure.  
 
2.4 Identifying the τ138 - τ131 interaction site  
As the efforts to obtain the structure of the τ131-τ138 complex were not successful, I 
decided to use existing structural information on the τ131 TPR array and analyse the 
surface conservation and validate known mutational data from the literature 
biochemically. It was hoped that this would provide clues as to which residues or 
regions may be involved in an interaction with τ138.  
 
2.4.1 Conservation and mutational analysis of the τ131 TPR array  
Surface representations of the τ131 TPR array are displayed in Figure 2.15. Conserved 
regions occur on both arms of the array and in the groove between the two arms. The 
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extended helix and RING are poorly conserved (Figure 2.16 and also Figure 2.4). The 
TPR array contains a mixture of acidic and basic patches, some of which overlap with 
regions of conserved residues. The τIR region of τ138 is largely basic (Figure 2.7) 
suggesting that acidic residues of the TPR array could form part of the interaction site.  
 
 
Figure 2.15 TPR array surface conservation and electrostatics. (A) View reproduced from Figure 2.4. (B) 
Surface conservation representation. Conserved residues are coloured as shown in the legend. (C) 
Surface electrostatics coloured as shown in the legend. 
 
Mutation of residues involved in protein-protein interactions may disrupt binding. 
Therefore, I mapped previously characterised mutations of τ131 onto the TPR array 
structure (Figure 2.17). The mutations that increase Pol III transcription cluster mostly 
on TPR 2, those that decrease Pol III transcription spread over TPRs 6-9 and those that 
rescue a τ138 temperature-sensitive mutation, G349E (see Introduction), map to TPRs 
7-8. Of particular interest were residues which, when mutated, rescued the τ138 
temperature-sensitive mutation, as this could imply a physical contact between τ131 
and τ138 at this region. Two of these residues – D468 and E498 – are both acidic and 
solvent-exposed, and so may make contact with the basic region of τ138 τIR. These 
residues occur on TPR 8 of the τ131 TPR array and so I decided to focus on this region 
in my next experiments.  
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Figure 2.16 Sequence and structural alignment of the TPR array of τ131. Residues are coloured 
according to the legend in Figure 2.15. A structural alignment using predictions of the S. pombe and H. 
sapiens sequences are displayed above the sequences. Other aligned species featured are: Candida 
albicans, Gallus gallus and Arabidopsis thaliana. Coloured asterisks (*) indicate highlighted mutants 
displayed in Figure 2.17.  
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Figure 2.17 Mapping known mutants onto the τ131 TPR array. Boxed in green are residues associated 
with an increase in Pol III transcription. Boxed in red are residues associated with rescuing a 
temperature-sensitive τ138 mutant. Boxed in blue are residues associated with a decrease in Pol III 
transcription. Note that residue H190 was also shown to rescue the τ138 temperature-sensitive 
mutation.  
 
2.4.2 Selecting and purifying τ131 TPR 8 point mutants  
To further map the interaction site for the τ138 τIR, I generated five point mutants in 
TPR 8 of τ131 (D468K, E498K, L468K, E472K, and E497K). These residues were selected 
based on the analysis just described and are highlighted in Figure 2.18. The residues 
were all mutated to lysine to create a charge-swap in most cases. Mutagenesis cloning 
was carried out as detailed in Materials and Methods, 6.1.10. The untagged proteins 
were purified by the same protocol as used for the wildtype τ131 (123-566).  
Analytical gel filtration was used as a quality control to ensure that the proteins 
remained folded correctly and were not aggregated (Figure 2.19).  
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Figure 2.18 Conservation of residues in TPR 8 of the τ131 TPR array. (A) Close-up view of residues 
selected for mutation, located in TPR 8 (red) of the TPR array (grey). Residues D468, L469, E472, E497 
and E498 are displayed as sticks and coloured according to conservation. These residues are highlighted 
on the sequence alignment in B by purple (D468, L469, E472, E497) or dark grey (E498) arrowheads. (B) 
Sequence alignment of TPR 8. Colour code for conservation is the same as in Figure 2.15. 
 
 
 
Figure 2.19 Analytical gel filtration profiles of the TPR array of τ131 and various mutants. The samples 
were injected onto a Superdex 200 10/300 GL column (GE Healthcare) and elution position was 
analysed. wt = wildtype.  
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2.4.3 Testing τ131 mutants by GST pull-down 
The same assay that I had established for initially mapping the τ131-τ138 interaction 
was used to test the τ131 mutants for interaction with τ138. The GST-tagged protein 
used in the assay was τ138-τIR. Figure 2.20 shows the results of the assay.  
 
 
Figure 2.20 Residues D468 and L469 are important for τ138 interaction. GST pull-down assay. 12% SDS-
PAGE of pull-down (top) and input (bottom) samples are shown. M = marker; wt = wildtype; mt = 
mutant. 
 
The first lane is the positive control, showing the previously obtained result that τ138 
τIR pulls down the τ131 TPR array. Mutants D468K and L469K are not pulled down by 
τ138-τIR. Mutants E472K and E498K are pulled down, but the intensity of the τ131 
band is weaker than for the wildtype. The E497K mutant appears to be pulled down as 
efficiently as the wildtype. It can be concluded from this assay that the D468 and L469 
residues are very important for the τ138 interaction, as the binding is abolished when 
these two residues are mutated.  
 
2.4.4 Testing τ131 mutants by ITC 
I again used ITC in order to quantitatively analyse the interaction between the τ131 
mutants and τ138. I tested both the τ138 τIR and the τ138 winged helix + τIR (546-693) 
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by ITC for binding to the τ131 mutants. The results were again consistent with the 
results I observed for the GST pull-down. The ITC results are shown in Figure 2.21 and a 
summary of binding affinities is displayed in Table 2.2. 
 
Table 2.2 Summary of Kd values from ITC experiments between τ131 TPR mutants and τ138 
 
 
 
 
 
 
 
 
                                       N.B. = No binding 
 
Again, the D468K and L469K mutations lead to a loss of binding with τ131. Mutations 
E472K and E498K cause an approximate 10-fold reduction in binding, whilst mutant 
E497K shows almost identical binding affinity as the wildtype. In summary, the findings 
from ITC experiments fully confirm the observations from the GST pull-down assay. 
The results suggest that the τ138 τIR binds, at least in part, to residues in TPR 8 of the 
τ131 TPR array.  
 
2.5 Investigating τ131-Bdp1 interaction.  
Unexpectedly, the binding site for τ138 overlapped with a reported binding site for 
Bdp1, an essential subunit of TFIIIB. Bdp1 is hypothesised to form contacts with both 
arms of the τ131 TPR array, competing with another TFIIIB subunit, Brf1 [109]. The 
mutation D468N causes a reduced two-hybrid response to Bdp1 [104] whilst L469K 
decreases the interaction with Bdp1 in vitro and in vivo [109]. I decided to test by GST 
pull-down assay whether the TPR array could interact with Bdp1 full-length protein, 
and whether this interaction could be disrupted by the τ131 mutants I had already 
characterised for the τ138 interaction.  
 
 
τ131 TPR array τ138 (τIR) τ138 (WH+τIR) 
wildtype 80 nM 100 nM 
D468K N.B. N.B. 
L469K N.B. N.B. 
E472K 833 nM 415 nM 
E497K 89 nM 99 nM 
E498K 833 nM 971 nM 
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2.5.1 Testing τ131-Bdp1 interaction by GST pull-down 
To test for τ131-Bdp1 interaction, I used full-length Bdp1 protein, kindly provided by 
Niklas Hoffmann, a PhD student in our lab. I first tested the interaction between the 
τ131 TPR array and Bdp1 by GST pull-down.  
 
Figure 2.22 τ131 binds full-length Bdp1 but not in the presence of τ138 (WH-693). GST pull-down assay 
to investigate τ131-Bdp1 interaction. 12% SDS-PAGE pull down and input gels. * = sample investigated 
for different experiment; M = marker. 
 
The τ131 TPR array, fused to GST, pulled down full-length Bdp1 (Figure 2.22). This 
result is expected based on previous literature but is the first time, to the authors’ 
knowledge, that this has been demonstrated using recombinant, purified proteins. 
Bdp1 alone did not bind to the GST-affinity resin, or to GST acting as negative controls.  
I then checked if the τ138 τIR could out-compete the Bdp1 for binding to the 
TPR array. To this end, I incubated GST-τ138 (WH-693), τ131 (123-566) and full-length 
Bdp1 together with the GST-affinity resin and performed the pull-down experiment as 
before. Figure 2.22 shows that the τ138 pulls down τ131 as expected but with no pull-
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down of Bdp1. This suggests that the τ138 τIR can indeed out-compete Bdp1 for 
binding to the τ131 TPR array.  
 
2.5.2 Overlapping binding sites of  τ131, Bdp1 and τ138 
I next tested whether the residues D468 and L469 were significant for the interaction 
between τ131 and Bdp1, as I had shown for the interaction between τ131 and τ138. To 
this end, I repeated the GST pull-down assay but this time tested the GST-tagged Bdp1 
for binding with τ131 D468K and L469K. The results are shown in Figure 2.23.  
 
 
Figure 2.23 The τ131-Bdp1 interaction is also be affected by mutants D468K and L469K. GST pull-down 
assay to investigate τ131 point mutants-Bdp1 interaction. 12% SDS-PAGE pull down and input gels. τ138 
(WH-693) proteins are included for comparison. M = marker. 
 
54 
 
One problem with this experiment is the stability of the GST-Bdp1 construct. A 
degradation band which is visible at ~50 kDa overlaps with the position of the τ131 
band, thus interfering with the conclusion from this experiment. However, it would 
appear that the two point mutants (D468K and L469K) reduce the interaction between 
Bdp1 and τ131, owing to the fainter bands present at the τ131 position for the two 
mutants. This mirrors the situation observed for τ138, suggesting overlapping binding 
sites on the τ131 TPR array for τ138 and Bdp1.  
 
2.6 Discussion 
This chapter has detailed my findings that the TPR 8 of τ131 specifically interacts with a 
50 amino acid region of τ138, called ‘τIR’. My findings identified the first direct 
interaction site between τA and τB. Interestingly, this site overlaps with τ131’s binding 
site for the TFIIIB subunit Bdp1. 
 
2.6.1 The TPR array of τ131 links τA and τB  
TFIIIC is described in the literature as a ‘dumb-bell’ shaped molecule formed of two 
DNA-binding subcomplexes called τA and τB. These two subcomplexes are proposed to 
be connected by a flexible linker. A low resolution view of this linker was obtained by 
early scanning electron microscopy images and supported by proteolysis studies [68, 
75]. To identify the subunits involved in this linker, I first used chemical cross-linking 
studies coupled with mass spectrometry. These results provided a clear indication that 
τ131 and τ138 were in close proximity to each other. This was consistent with a 
previous study that identified point mutations within the τ131 TPR array that suppress 
the temperature-sensitive τ138 mutation, G349E.  
I have shown that the highly conserved TPR array within τ131 binds and 
stabilises a central region of τ138 I call ‘τIR’. It is unclear how τIR interacts at the 
molecular level with the TPR array. It may form an extended interface as with other 
TPR-‘peptide’ structures [149], possibly wrapping around both the convex and concave 
surface of the TPR array to exploit the larger surface area. In the absence of a crystal 
structure of the complex between the TPR array and the τ138 τIR, this remains an open 
question. Despite extensive efforts, I was not able to locate additional density for the 
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τ138 τIR within the ‘complex’ crystals. A crystal of the complex was run on SDS-PAGE 
to ensure that the τ138 τIR was present in the crystals (Figure 2.24). 
 
 
Figure 2.24 Confirmation that the τ138 τIR is present in the complex crystals. (A) A complex crystal was 
dissolved in 5x SDS buffer and ran on an 18% SDS-PAGE. A smeared band at ~10kDa indicates the 
presence of the τ138 τIR. (B) A lane from Figure 2.10B showing the purified complex as a comparison.  
 
With the gel indicating the presence of the τ138 τIR, what explanations are there for 
the lack of electron density in the crystal lattice? One explanation could be that the 
observed precipitate surrounding the crystals is in fact the denatured τ138 τIR and that 
the protein degrades over time, although this is not indicated by the gel in Figure 2.24. 
Another explanation could be that within the crystal lattice there is not a sufficient 
number of τ131 molecules bound to the τ138 τIR, and that the two components should 
instead be purified separately and co-crystallised with a molar excess of the τ138 τIR to 
increase the likelihood of observing electron density for this part of the complex.  
Despite the lack of structural information for this interaction, I showed that the 
τ138 τIR binds to TPR 8 of τ131 and I have identified key residues involved in this 
interaction. As the τIR comprises 50 amino acids and as it appears that the entire 
length is required for high affinity-affinity binding, it would seem reasonable that the 
τIR also binds at other locations within the TPR array. It was surprising to observe a 
complete loss of binding upon mutation of either residue D468 or L469 to lysine. These 
highly conserved residues occur on TPR 8 (Figure 2.18): D468 points into the inner 
groove, whilst L469 makes hydrophobic contacts with the A helix of TPR 7. Both 
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residues are located close to the ‘hinge’ between the two arms of the TPR array and so 
it might be possible that mutation of these residues leads to a change in the 
positioning of the two arms relative to each other. This could explain why they are 
important for the interaction with τ138 and also Bdp1 (see below), although direct 
interaction through these residues is still a possibility.  
A more extensive mutational analysis could be carried out, firstly in vitro, in 
order to assess where else the τ138 τIR may bind on the TPR array. However, this task 
would be made far easier by a structure-guided mutagenesis approach. As the τ131-
τ138 complex does not appear to be amenable to studying by X-ray crystallography in 
S. cerevisiae, studying the interaction in other species may represent a possible future 
direction. 
 
2.6.2 Conservation of the link between τA and τB  
As highlighted in the Introduction there are a number of apparent differences between 
TFIIIC in S. cerevisiae and the TFIIIC of other eukaryotes, such as humans. The 
divergence of subunits between the two is most pronounced within the subunits of τB. 
Whilst τA subunits show high sequence and structural conservation the τB subunits are 
less conserved, particularly τ138. Figure 2.5 shows that the τ138 orthologue in humans 
(TFIIIC220) is in fact double the size and poorly conserved on an overall sequence level. 
There is however some structural conservation, particularly at the N-terminus, which 
appears to contain three winged helix domains.  
The TPR array of τ131 is highly conserved, with the overall architecture of the 
TPR array apparently required from yeast to human (see Figure 2.4, Figure 2.15 and 
Figure 2.16). On the other hand, the τIR of τ138 is not well conserved. There is some 
sequence conservation, when comparing S. cerevisiae with S. pombe (Figure 2.7C), but 
the τIR aligns very poorly with sequences from other eukaryotes, such as human. What 
is clear is that the region after this winged helix is relatively disordered in all species, 
however the size and sequence of this region varies.  
As suggested in Section 2.6.1, one could attempt to produce equivalent 
constructs in other species such as S. pombe or Chaetomium thermophilum and test if 
a complex is still formed. This would probably require new construct screening projects 
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for homologues from higher eukaryotes, as the τIR region of τ138 is not very well 
conserved and so predicting and delineating boundaries would prove difficult.  
 
2.6.3 Do τ131 and τ138 form the only link between τA and τB? 
Although I have shown that τ131 and τ138 form a link between τA and τB, other TFIIIC 
subunits may be involved as well. Previous work has cited τ60 and τ95 as making links 
between τA and τB [90, 101]. However, no cross-links were observed between τ60 and 
τA subunits in the experiments I presented in this chapter. In contrast, there were 
cross-links between τA component τ95 and τB component τ138, which supports a role 
for the involvement of this subunit in linking τA and τB. A previous study has shown 
binding of τ95 to τ138 by co-immunoprecipitation, and described a point mutant 
within τ95 (E447K) that reduces the affinity of TFIIIC towards tDNA [90]. The τ95 
subunit may bind to τ138 directly, or be brought into close proximity to τ138 by the 
interface with the τ131 TPR array, as τ95 has been shown to bind this TPR array in 
humans [88] and in S. pombe in unpublished data from our lab. 
Although no other cross-links were observed between τA and τB subunits the 
participation of other subunits, or indeed the already characterised subunits at 
additional sites, cannot be ruled out at this point. An absence of cross-linking may be 
due to low accessibility of the cross-linker to a tightly buried interface (such as the 
WD40s of τ60-τ91, where no cross-links are observed) or the absence of required 
lysine residues in the respective interface, and so there may be other regions within 
TFIIIC which do indeed interact but are undetectable by this method.  
 
2.6.4 The overlapping binding sites of τ138 and Bdp1 on τ131 
The TPR array of τ131 and its crucial role in the assembly of TFIIIB has been the subject 
of extensive studies. It was intriguing that the residues that I identified as being crucial 
for the τ131-τ138 interaction had already been implicated in Brf1 and Bdp1 binding 
[104, 109], suggesting that the binding sites for these subunits overlap on the TPR 
array. I have presented preliminary pull-down analysis comparing the effect of τ131-
Bdp1 interaction with τ131-τ138 interaction. It is clear that the TPR array provides a 
platform over which Bdp1 binds stoichiometrically, which is consistent with previous 
studies. In addition, the pull-down suggests that Bdp1 binding is affected by the 
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mutations D468K and L469K in vitro and in vivo. For this last experiment it is difficult to 
make a firm conclusion however, as the position of the τ131 band overlaps with a 
degradation band of Bdp1. Bdp1 is predicted to be a largely disordered protein and 
producing recombinant full-length protein has proved difficult. Nevertheless, these 
initial findings are consistent with the literature and are supported by the experiment 
shown in Figure 2.22. Here, incubation of Bdp1 and τ131 with GST-τ138 led to only the 
pull-down of τ131 suggesting that Bdp1 is outcompeted for binding when τ138 is 
present. Further work will be required in order to investigate precisely the regulatory 
mechanisms involved. 
In summary, I have demonstrated that τA subunit τ131 uses its TPR array to link 
τA with τB, binding with high affinity to a disordered region C-terminal to a conserved 
winged helix domain in τ138. This is the first structurally and biochemically mapped 
interaction site between a τA and a τB component of TFIIIC, which in addition overlaps 
with a TFIIIB binding site. 
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 Results - Structural and Functional Studies on τ138 3.
From the project described in the last chapter, a region of τ138 was identified that 
formed a high-affinity interaction with τ131. N-terminal to this region was a domain 
that was predicted to be a winged helix (546-641). I set out to crystallise this fragment 
and learn more about the role of τ138 within TFIIIC.  
 
3.1 Solving the structure of τ138 (546-641) 
3.1.1 Purification of τ138 (546-641)  
The reader is referred to Materials and Methods for full details of cloning, expression 
and purification protocols. A pETM30 vector encoding the sequence for τ138 (546-641) 
was expressed in BL21 (DE3) Gold E. coli cells. The protein was purified by means of an 
N-terminal, TEV protease-cleavable 6x-histidine tag adjacent to a GST-tag. After elution 
from nickel resin, the 6x-histidine-GST tag was cleaved by TEV protease and the 
cleaved protein was collected. The protein was injected onto a S75 Superdex 
preparative gel filtration column (GE Healthcare) and eluted at an expected position 
for a monomer and as a single species (Figure 3.1A). Analytical ultracentrifugation 
(AUC) was carried out in collaboration with Vladimir Rybin at EMBL Heidelberg, again 
confirming a single species at the expected molecular weight of ~11 kDa (Figure 3.1B). 
The protein was evaluated by SDS-PAGE and judged to be appropriate for 
crystallisation trials (Figure 3.1A).  
 
 
Figure 3.1 Biophysical characterisation of τ138 (546-641). (A) Analytical gel filtration profile of τ138 
(546-641). The sample was injected onto a Superdex 200 10/300 GL column (GE Healthcare) and elution 
position analysed. Positions of known molecular weight standards are indicated at 17 kDa and 1.4 kDa. 
Inset, 15% SDS-PAGE showing elution peak. (B) Analytical ultracentrifugation profile of τ138 (546-641).  
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3.1.2 Crystallisation of τ138 (546-641) 
The protein was concentrated to 30 mg/mL and used for initial crystallisation trials. 
Crystals were grown at 20°C using the sitting drop method in an initial broad screening 
approach. Initial crystals were obtained in the JCSG+ screen (Molecular Dimensions) 
with a reservoir solution of 1 M sodium citrate pH 6.5 and 0.1 M sodium cacodylate 
(Figure 3.2A). Manual refinement screens were set up around this condition with the 
best hits occurring in 1.15 M sodium citrate pH 6.2 and 0.1 M sodium cacodylate 
(Figure 3.2B). Crystals were cryo-protected by soaking in mother liquor supplemented 
with 15% glycerol for a few seconds before being flash-frozen in liquid nitrogen. 
 
 
Figure 3.2 Crystallisation and diffraction of τ138 (546-641). (A) Initial crystal obtained for τ138 (546-
641). (B) Refined crystals that were used for data collection. (C) Collected crystal in a loop for data 
collection. (D) Example of a diffraction image taken for the crystal collected in C. 
 
3.1.3 Solving the structure of τ138 (546-641) by sulphur-SAD 
The crystals diffracted to ~1.9 Å on the rotating anode X-ray home source at the EMBL 
Heidelberg. As initial molecular replacement solutions were not successful, an 
uncommon approach to structure solving was tried, namely sulphur-SAD. This 
technique for solving structures was first demonstrated in 1981 [150]. Sulphur-SAD 
relies on the very small but useable anomalous signal from sulphur atoms that are 
present in methionine or cysteine residues of proteins. The anomalous signal arises 
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from the excitation of specific electrons of the sulphur atom, which occurs at a so-
called ‘absorption edge’ (different elements possess different edges). This edge, where 
a sharp increase in absorption of X-rays by the electrons of a specific element occurs, is 
accessed at specific X-ray wavelengths. The wavelength of X-rays produced by a copper 
anode (present in our home source) is relatively close to the sulphur edge. The signal 
produced is very small, especially when compared to the anomalous signal from 
selenium that is recorded in selenomethionine substituted protein crystals (Figure 3.3).  
 
 
Figure 3.3 The anomalous signal from the sulphur-edge is very small when compared to the selenium-
edge. (A) Edge plot for selenium. The so-called absorption edge can be easily appreciated, indicated by 
the arrow. (B) Edge plot for sulphur. The arrow indicates the wavelength at which experiments were 
performed. F’’ (bold magenta line) represents anomalous differences, f’ (light magenta line) represents 
dispersive differences. Both differences contribute to the overall scattering by the atom. e = electrons. 
Edge plots were generated using the webserver: http://skuld.bmsc.washington.edu/cgi-bin/edgeplots.  
 
A highly redundant data collection (540 images, 1° rotation) was carried out – essential 
for accurately recording the small anomalous signal – and data was processed using 
XDS [144] (see Materials and Methods, 6.4 for further details on data processing).  
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Table 3.1 τ138 (546-641) Data collection, phasing and refinement statistics 
 τ138 (546-641)  
Sulphur-SAD 
τ 138 (546-641)  
Native 
Data collection1   
X-ray source Rotating anode (EMBL) ID23-1 (ESRF) 
Space group R32 R32 
Cell dimensions 
    a, b, c (Å) 
129.05, 129.05, 68.11 
 
129.09, 129.09, 68.04 
 
   
Wavelength (Å) 1.54180 0.97630 
Resolution (Å) 50-1.86 (1.91-1.86)  50-1.40 (1.44-1.40) 
CC 50 1.0 (0.92) 0.99 (0.65) 
Rmerge (%) 5.9 (63.7) 5.1 (137.9) 
I/σI 40.31 (4.57) 21.31 (1.73) 
Completeness (%) 99.9 (99.6) 99.9 (99.3) 
Redundancy 15.6 (13.6) 10.1 (9.4) 
Sites 6 S - 
   
Refinement   
Resolution (Å)  43.2 – 1.40 
No. reflections  42552 
Rwork/ Rfree (%)  16.3/19.4 
No. atoms   
    Protein  1545 
    Water 
    Ligand 
 246 
12 
B-factors (Å2)   
    Protein  27.3 
    Water 
    Ligand 
 37.1 
57.8 
R.m.s deviations   
    Bond lengths (Å)   0.017 
    Bond angles (°)  1.656 
1 Values in parentheses correspond to the highest-resolution shell 
 
The statistics of the integrated reflection data showed that the data was highly precise 
(as judged by low Rmerge values) and that the overall resolution extended to 1.9 Å 
carrying reliable anomalous signal up to 3.4 Å. The structure was solved by SAD 
combined with density modification using the program autoSHARP [148], with the 
program able to locate the positions of 6 sulphur atoms, indicating 2 molecules in the 
asymmetric unit (Figure 3.4B). The two molecules of the asymmetric unit are related 
by a non-crystallographic dyad.  
An initial build using AutoBuild [151] in the Phenix suite [147] was followed by 
iterative rounds of real-space model building in Coot [146] and reciprocal-space 
refinement in Phenix. Water molecules could be modelled owing to the high-resolution 
density. The resolution was later extended to 1.4 Å using a native dataset collected at 
beamline ID23 at the ESRF (Figure 3.2D). The quality of this high-resolution electron 
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density is highlighted in Figure 3.4C. The final model could be refined to Rwork/Rfree 
values of 16.3%/19.4% with good stereochemistry (Table 3.1). 
 
3.1.4 τ138 (546-641) is an extended winged helix domain 
The crystal structure revealed that this domain is in fact an ‘extended’ winged helix 
(eWH). The canonical winged helix fold (α1, β1, α2, α3, β2, β3) is observed but an 
additional C-terminal alpha-helix (α4) is present (Figure 3.4A). The name ‘extended’ 
winged helix was used originally by Meinhart et al. [51]. In that example, the canonical 
winged helix of TFIIE was extended both at the N-terminus and the C-terminus. 
 
Figure 3.4 Structure of the central eWH domain (546-641) of τ138. (A) Two views of the eWH domain 
are displayed in ribbon representation with a transparent surface representation superimposed. A 
schematic of the arrangement of alpha-helices and beta strands is displayed underneath. Cylinders 
depict α-helices, arrows depict β-strands. (B) The eWH domain with sulphur electron density peaks 
highlighted in magenta at the three methionine positions. (C) A close-up of the loop between β3 and α4 
highlights the excellent electron density. 2mFo-DFc map contoured at 1σ.  
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3.2 Functional analysis of the central eWH domain of τ138 
A DALI sever search [152] revealed many winged helix domains, but none that 
superimposed well in terms of the extended α4 helix. I thus investigated the structure 
in more depth to provide clues of a potential function.  
 
3.2.1 Surface conservation and electrostatics of the eWH domain 
The structure is relatively well conserved at a sequence level from yeast to human 
(Figure 3.5). Moreover, the eWH fold is almost completely preserved when comparing 
the structure prediction of S. cerevisiae, S. pombe and H. sapiens (Figure 3.5). 
 
 
Figure 3.5 eWH domain surface conservation and electrostatics. (A) View reproduced from Figure 3.4. 
(B) Surface conservation representation. Conserved residues are coloured as shown in the legend. (C) 
Surface electrostatics coloured as shown in legend. (D) Sequence alignment of the eWH domains of five 
selected species. Residues are coloured according to the legend in B. Structural alignment using 
predictions of the S. pombe and H. sapiens sequences are displayed above the sequences. Cylinders 
depict α-helices, arrows depict β-strands. 
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In terms of surface conservation, there are patches of conserved residues on both 
faces of the eWH domain (Figure 3.5B). Of particular interest are the conserved basic 
residues at the start of α3 (the so called ‘recognition-helix’) and the ‘wing’ between β1 
and β2. These sites are often associated with binding nucleic acids. The eWH domain 
also contains a large acidic patch at the top of the molecule (Figure 3.5C), in part from 
contribution of the additional helix α4. However, this appears to be non-conserved. 
  
3.2.2 Testing for DNA-binding of the eWH domain 
With several basic patches present on the surface of the eWH domain I next decided to 
test the eWH domain for nucleic acid binding using electrophoretic mobility shift assay 
(EMSA). I used a radioactively labelled (32P) oligonucleotide that was 66 bases in length 
and represented the sequence of a tDNA encoding tRNAGlu, see Materials and 
Methods, 6.2.4 for details. This oligonucleotide had been shown to bind holo-TFIIIC 
with moderately high affinity and thus appeared suitable for testing fragments of τ138 
(Figure 3.12). The eWH domain was tested for binding to this single-stranded (ss) and 
double-stranded (ds) oligonucleotide at varying concentrations (Figure 3.6).  
 
 
Figure 3.6 The eWH domain does not bind specifically to single-stranded (ss) or double-stranded (ds) 
tDNAGlu. (A) EMSA experiment of eWH domain binding to a ssDNA 66bp tDNAGlu oligonucleotide. (B) 
EMSA experiment of eWH domain binding to a dsDNA 66bp tDNAGlu oligonucleotide. Top arrows indicate 
the shifted eWH-DNA complex and lower arrows indicate free DNA. * = excess of single-stranded DNA 
after annealing. C = control experiment (no protein added).  
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Binding to both ssDNA and dsDNA was not observed until a protein concentration of 
500 µM was reached, indicating non-specific binding of the eWH domain to DNA. I 
therefore concluded that the central eWH domain of τ138 does not specifically bind to 
tDNA. 
In summary, I solved the structure of a conserved central extended winged helix 
domain of τ138. In the former chapter I described that this domain was not involved in 
the τ131 TPR array interaction. Here, I have shown that this domain is also not involved 
in binding DNA. Curious as to which part of τ138 is responsible for B box binding, I set 
out to generate further constructs of τ138 for structural and functional studies.  
 
3.3 Construct mapping of τ138 
Full-length τ138 from S. cerevisiae could be expressed in E. coli and insect cells but was 
mostly insoluble and rapidly degraded after lysis. Consequently, I turned to designing 
smaller fragments of τ138 for structural and functional studies in E. coli with the aim of 
identifying the B box binding region.  
 
3.3.1 Secondary structure prediction and alignment of τ138 
By comparing various structure prediction servers (e.g. Phyre2 [153] , HHPred [154] 
and GeneSilico [155]) and alignment of orthologues found in other species, a 
consensus for secondary structure elements for τ138 was reached. Figure 3.7 
highlights predicted secondary structure elements for S. cerevisiae τ138. As highlighted 
in the previous chapter, τ138 is predicted to contain many winged helix domains, an 
arrangement which appears to be conserved from yeast to human, particularly for the 
three N-terminal winged helix domains and the central eWH domain (Figure 2.5). HMG 
box domains are also predicted at the extreme N and C-terminal ends of the protein, 
whilst the region after the disordered τIR (641-693) is largely helical. HMG-box 
domains, as with winged helix domains, are implicated in binding and bending DNA, 
either sequence specifically or non-specifically [95, 156]. Both domains have also been 
shown to mediate protein-protein interactions.  
I designed constructs to ‘scan’ structured regions of τ138, attempting larger 
constructs in the first instance before focussing on smaller regions that would 
encompass isolated or tandem domains. Particular attention was paid to the 
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boundaries of these predicted elements when designing constructs. I ensured that 
constructs had small hydrophilic residues, usually serine residues, at the termini 
whenever possible to minimise risk of aggregation.  
 
 
Figure 3.7 Predicted secondary structure elements of τ138. The upper bar represents the τ138 
sequence, with predicted secondary structure elements highlighted. HMG = high mobility group; WH = 
winged helix; τIR = τ131-Interacting Region. The central eWH domain and τIR are highlighted in dark 
green and light green respectively. Underneath the top bar is a representation of predicted α-helices 
(pink) and β-strands (blue). Predicted disorder is represented underneath this by a jagged line, the lower 
line the higher the predicted confidence of disorder. Constructs coloured black were expressed but were 
not soluble. Constructs in blue were expressed and soluble but only with the GST tag. Constructs below 
the dashed line and coloured green were soluble without the GST tag and were stable on gel filtration. 
 
3.3.2 Workflow for τ138 construct screening 
I employed an iterative workflow for this project (Figure 3.8). Cloning was carried out 
using the pETM30 system, which introduces an N-terminal, TEV protease-cleavable 6x-
histidine-GST tag. Expression and solubility tests were carried out in parallel, on a 
small-scale, with promising constructs (i.e. soluble and well-expressed) then taken to 
large scale for purification and analysis (Materials and Methods, 6.2). It should be 
noted that the biggest challenge for this project was protein solubility, with most 
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proteins either ending up in the pellet after cell lysis or becoming insoluble after the 
GST tag was cleaved off. In total I tested 41 constructs, of which 11 were soluble 
without the GST tag and were stable on gel filtration. This approach focused on a semi-
high-throughput construct pipeline and the majority of the iterations of my workflow 
were centred on the N-terminus of τ138. This was because the N-terminal half of TFIIIC 
appeared most conserved when comparing yeast TFIIIC to human TFIIIC (Figure 2.5) 
[103] and so seemed a more suitable candidate for B box binding.  
 
 
Figure 3.8 Workflow for screening τ138 constructs.  
 
3.4 Characterising an N-terminal τ138 fragment (1-179) 
After several iterative rounds, an N-terminal construct (1-179) was identified as 
expressed and soluble by my workflow. The construct is predicted to contain a HMG-
box domain and a winged helix domain (Figure 3.7). 
 
3.4.1 Purification of τ138 (1-179)  
Cloning, expression and purification of this protein was carried out using the same 
protocol as for the eWH domain (Section 3.1.1). After elution from nickel resin, the 6x-
histidine-GST tag was cleaved by TEV protease and the cleaved protein was collected 
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(Figure 3.9A). The protein was then injected onto a Superdex 75 preparative gel 
filtration column (GE Healthcare) and eluted at an expected position for a monomer 
and as a single species (Figure 3.9B). The protein was evaluated by SDS-PAGE and 
judged to be appropriate for crystallisation trials. 
 
 
Figure 3.9 τ138 (1-179) can be purified to homogeneity. (A) 12% SDS-PAGE showing TEV protease 
cleavage of τ138 (1-179). T = TEV protease; FT = flow-through. M = marker. (B) Analytical gel filtration of 
τ138 (1-179). The sample was injected onto a Superdex 75 10/300 GL column (GE Healthcare) and 
elution position analysed. N.B. the second narrow peak was as a consequence of an overpressure on the 
system. 15% SDS-PAGE of elution peak is shown underneath the gel filtration profile.  
 
3.4.2 Crystallisation of τ138 (1-179) 
The protein was concentrated to 30 mg/mL for initial crystallisation trials. Crystals 
were grown at 20°C and at 4°C using the sitting drop method in an initial broad 
screening approach. Initial crystals were obtained in the Wizard I and II screen (EMBL 
Heidelberg Crystallisation Platform) with a reservoir solution of 0.1 M sodium acetate 
pH 4.5 with 0.8 M sodium phosphate and 1.2 M di-potassium phosphate at 20°C. 
Refinement screens were set up around this condition, both at 20°C and at 4°C.  Figure 
3.10 provides typical examples of crystals that were tested for this protein. 
Reproducibility of these crystals was very challenging. Using flash-frozen and 
then thawed protein resulted in reduced crystal quality, thus requiring a fresh 
preparation before each crystallization trial. Furthermore, several concentrations of 
glycerol and other compounds such as PEG400 had to be tested for cryo-protection as 
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the crystals appeared to suffer from cracking upon freezing. Crystals grown at 4°C 
appeared more robust and larger, but provided un-interpretable diffraction patterns. 
Crystals grown at 20°C grew in clusters that proved difficult to collect, but did 
occasionally produce clear diffraction patterns. Resolution was limited to 4-6 Å 
however.  
For now, the structure of this protein remains unsolved. The best dataset 
currently extends to 3.8 Å but no molecular replacement solution could be found. 
Furthermore, no selenomethionine incorporated protein crystals were successfully 
grown up to now.  
 
 
 
Figure 3.10 Crystallisation and diffraction of τ138 (1-179).  (A) Crystal grown at 4 °C. (B) Collected 
crystal in a loop for data collection. (C) Example of a diffraction image taken for the crystal collected in B. 
(D) Crystal grown at 20 °C. (E) Collected crystal in a loop for data collection. (F) Example of a diffraction 
image taken for the crystal collected in E. 
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3.4.3 Testing for DNA-binding of τ138 (1-179) 
With no structure available, but with the construct predicted to contain two potential 
DNA-binding domains, I carried out an EMSA experiment as I had done for the eWH 
domain (Section 3.2.2). I used the same 66 base oligonucleotide as previously (see 
Materials and Methods, 6.2.4). The protein was tested for binding to ssDNA and dsDNA 
oligonucleotides at varying concentrations. The results of the single-stranded 
experiment are displayed in Figure 3.11. Binding to ssDNA was not observed until a 
protein concentration of 500 µM was reached, indicating non-specific binding of the 
eWH domain to DNA. The same was observed for dsDNA (data not shown). I therefore 
concluded that τ138 (1-179) does not bind specifically to tDNA. 
 
 
Figure 3.11 τ138 (1-179) does not specifically bind single-stranded (ss) tDNAGlu. EMSA experiment of 
τ138 (1-179) binding to a ssDNA 66 base tDNAGlu oligonucleotide. Top arrow indicates the shifted τ138 
(1-179)-DNA complex and the lower arrow indicates free DNA. C = control experiment (no protein 
added). 
 
3.5 Cross-linking TFIIIC when bound to tDNA  
Producing soluble fragments of τ138 to test for DNA-binding, proved more challenging 
than expected and the two fragments that could be tested (546-641 and 1-179) did not 
bind tDNA. I reasoned that using the cross-linking coupled with mass spectrometry 
approach that was employed previously could provide useful information instead. The 
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rationale was that it might be possible to identify regions within TFIIIC that are altered 
upon DNA-binding, by comparing the cross-links obtained with unbound TFIIIC. 
 
3.5.1 Binding TFIIIC to tDNA 
The 66 base tDNAGlu oligonucleotide used in the previous EMSAs had been selected 
based on the fact that TFIIIC binds to it with moderately high affinity. Figure 3.12 
shows a clear band-shift at 500 nM tDNAGlu indicating the specific binding of TFIIIC to 
the previously used tDNA oligonucleotide.  
 
 
Figure 3.12 TFIIIC binds the 66bp double-stranded tDNAGlu with high affinity. EMSA experiment of 
TFIIIC binding to a dsDNA 66bp tDNAGlu oligonucleotide. Top arrow indicates the shifted TFIIIC-DNA 
complex and the lower arrow indicates free DNA. C = control experiment (no protein added).  
 
3.5.2 Comparing TFIIIC cross-links when bound to tDNA  
TFIIIC was incubated with the oligonucleotide as described in Materials and Methods, 
6.2.5. Chemical cross-linking coupled with mass spectrometry was performed as 
described before (see also Materials and Methods, 6.1.2).  
 Table 3.2 lists the obtained inter-subunit cross-links from both DNA-bound and 
DNA-unbound TFIIIC cross-linking conditions. Of the 41 inter-subunit cross-links 
obtained over both conditions, 19 are detected in both conditions, 14 are unique to 
the DNA-unbound condition and 8 are unique to the DNA-bound condition. Table 3.3 
lists the obtained intra-subunit cross-links from both DNA-bound and DNA-unbound 
TFIIIC cross-linking conditions. Of the 107 intra-subunit cross-links obtained over both 
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conditions, 45 are detected in both conditions, 44 are unique to the DNA unbound 
condition and 18 are unique to the DNA bound condition. Figure 3.13 displays cross-
linking maps of TFIIIC unbound and bound to DNA.  
 
Table 3.2 – Inter-subunit cross-links of TFIIIC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     Prot. = Protein / Lys. = Lysine 
 
The link between τ131 and τ138 that was discussed in the previous chapter is 
maintained in both DNA-bound and DNA-unbound conditions. However, there are 
some differences observed between the cross-links obtained in other regions of these 
two subunits. There are two lysine residues outside the TPR array, K636 and K627, 
which cross-link to τ138 at the N and C termini respectively in the DNA-unbound 
condition that are not present when DNA is bound. These lysine residues are situated 
in a predicted disordered region of τ131 that contains many intra cross-links in the 
DNA-unbound condition. Over half of these intra cross-links are not present in the 
 Both conditions - DNA only + DNA only 
Prot. 1 Prot. 2 Lys. 1 Lys. 2 Lys. 1 Lys. 2 Lys. 1 Lys. 2 
τ60  τ91 124 130 124 153  
 124 139  
124 142 
τ60 τ138   124 506 
τ91 τ138  
 
178 478  
 598 433 
598 509 
610 414 
τ131 τ138 242 697 242 561 113 619 
242 698 412 689 242 642 
242 715 426 689 426 708 
349 729 627 885 426 715 
412 697 636 240  
426 697  
426 698 
τ131 τ55     113 211 
τ95 τ138 138 896 118 200  
141 896  
τ95 τ131 219 958 403 871 403 412 
395 871 631 947  
τ95 τ55 57 412  66 412 57 359 
66 359   
66 419 
123 419 
145 196 
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DNA-bound condition, suggesting that local conformational changes take place within 
this region of τ131 upon binding to DNA.  
 
Table 3.3 – Intra-subunit cross-links of TFIIIC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Both conditions - DNA only + DNA only 
Prot. 1 Prot. 2 Lys. 1 Lys. 2 Lys. 1 Lys. 2 Lys. 1 Lys. 2 
τ138 τ138 240 252 123 147 123 170 
348 252 153 139 348 247 
362 252 370 165 400 362 
362 257 383 478 401 362 
370 257 400 257 506  478 
370 362 414 383 506  619 
370 383 439 200 619 592 
478 483 491 509 619 637 
607 538 506 509 619 715 
689 637 506 538 708 729 
689 715 536 561 900 890 
697 715 536 607  
698 689 689 642 
698 715 698 639 
708 697 732 715 
708 715 767 715 
729 715 839 854 
767 729 900 1073 
896 885 930 900 
 930 1073 
τ91 τ91 139 130 142 591 178 130 
142 130 142 598 178 139 
142 161 153 130 503 139 
142 178 153 161 598 134 
142 503 153 503  
161 139 153 598 
161 178 161 130 
161 186 188 178 
178 186 591 130 
188 178 598 130 
503 130 634 610 
591 139  
591 161 
τ60 τ60 46 549 18 228 160 116 
53 5 116 556  
τ131 τ131 102 113 102 108  
513 506 513 678 
592 567 567 631 
637 631 581 567 
688 631 599 567 
702 627 599 607 
 627 567 
702 631 
τ95 τ95 48 123 48 57 243 251 
128 138 251 254 266 251 
128 145 408 403  
128 141  
637 627 
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Figure 3.13 Cross-linking map of TFIIIC unbound (A) and bound to tDNAGlu (B). TFIIIC subunits are 
represented as bars. Protein length is labelled at the C-terminus. Domains of which crystal structures are 
available are underlined. τ55 and τ95 Dim. = τ55 and τ95 dimerisation domains; DBD = DNA-binding 
domain; HPD = histidine phosphatase domain. The eWH domain and τIR are highlighted. Shaded green 
boxes on τ138 indicate predicted winged helix domains. Shaded red boxes on τ131 indicate predicted 
TPRs. Inter cross-links are depicted by lines connecting different subunits. Intra cross-links are depicted 
by arcs which connect residues within the same subunit.  
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47% of all intra cross-links (50) were detected for the τ138 subunit of TFIIIC. It is 
striking to observe that a large number of these intra cross-links occur between the 
predicted winged helix domains within the N-terminus of τ138, suggesting that the 
individual domains are in close spatial proximity to one another, perhaps even 
stabilising each other in the context of the entire protein. 40% of the τ138 intra cross-
links are lost when TFIIIC is bound to DNA, which could support the notion that these 
predicted winged helix domains bind DNA, potentially using lysine residues that may 
then not be able to react with the cross-linker.   
Both the τ60-τ91 and τ95-τ55 dimers do not appear to undergo drastic 
conformational changes with respect to the subunits within each dimer, as the inter 
and intra cross-links are generally present in both DNA-bound and DNA-unbound 
conditions (τ55 contains no intra cross-links in fact). I validated the intra cross-links of 
τ60 as they all occurred between lysine residues that are present in the previously 
solved crystal structure (Figure 3.14). The distances between these residues were all 
under 30 Å, thus satisfying the maximum distance permitted by the length of the cross-
linker. The τ95-τ55 dimerisation domain cross-links could not be validated as they 
generally occurred outside the structured interface or between residues that are not 
modelled in the structure (i.e. in disordered loops). 
 
 
Figure 3.14 Validating the intra cross-links of τ60. Distances between cross-linked lysine pairs were 
measured and are displayed as dashed red lines.  
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The most striking difference between the DNA-bound and DNA-unbound cross-linking 
conditions is a region of cross-links between τ91 and τ138. 4 cross-links are observed 
between the WD40 domain of τ91 and a disordered region of τ138 (414-509). None of 
these cross-links are detected when TFIIIC is bound DNA. This is highly intriguing given 
the predicted roles of τ138 and τ91 in contributing to B-box binding and will be 
discussed further below. 
 
3.6 Discussion  
This chapter has presented the first high resolution structure for the τ138 subunit of 
TFIIIC, an extended winged helix domain, which is conserved from yeast to human. In 
addition, initial crystals were obtained for the N-terminal fragment (1-179) of τ138. 
Cross-linking experiments have provided initial insights into a region of τ138 that may 
be responsible for B box binding and will be discussed below.  
 
3.6.1 What binds the B box of tRNA genes? 
The chemical cross-linking coupled to mass spectrometry results provided an intriguing 
finding which is consistent with previous data. Cross-links were observed between 
subunits τ91 and τ138 of TFIIIC that were subsequently not detected when TFIIIC was 
bound to tDNA (Figure 3.13). Several factors imply that this is not simply an 
experimental difference between the two conditions. For example, the ld scores of the 
cross-links when detected in the DNA-unbound state are above 25, strongly suggesting 
they are not false-positives. Furthermore, it is stochastically unlikely that all cross-links 
between τ91 and τ138 were simply not detected in the DNA-bound condition. What 
could explain this disappearance of cross-links? One explanation is that the binding of 
DNA in this region leads to steric hindrance of the cross-linker for solvent-exposed 
lysine residues in this region. Another explanation is that a significant rearrangement 
of domains occurs at this region upon DNA binding, which is further supported by the 
change in intra cross-links within τ138. Both explanations thus suggest that this region 
of τ138 is involved in binding to DNA. The region (414-509) where the cross-links are 
located is largely disordered and does not contain any known DNA binding domains, 
and so it is highly likely that DNA binding is mediated by one of the winged helix 
domains adjacent to it. As an aside, this situation is similar as for the τ131-τ138 cross-
78 
 
links previously discussed, as the links occur generally adjacent to the actual 
interacting region, probably because the actual interaction region is buried and so not 
accessible to cross-linking (also observed with τ60-τ91, see Section 2.6.3). As I have 
shown that the eWH domain does not bind DNA, the most likely candidate for DNA 
binding is thus the third predicted winged helix domain (Figure 3.15).  
 
  
Figure 3.15 A potential role for the third predicted winged helix domain in B-box binding. Lysine 
residues involved in τ91-τ138 crosslinking (without tDNA) are represented as green spheres on the τ91 
WD40 (purple) and as purple X’s on the τ138 schematic. The predicted position of the third winged helix 
is indicated between residues 330 and 420, and is consistent with secondary structure predictions. 
Residue G349 is highlighted (see main text for details). 
 
This is interesting for two reasons: 1) A temperature-sensitive mutation, G349E (see 
Introduction) occurs within this predicted winged helix domain and has been shown to 
reduce TFIIIC-tDNA binding [93]; 2) In a bioinformatics study, which also looked for B 
box binding conservation in bacteria and archaea, this area has been identified as a 
highly conserved region within the relatively poorly conserved τ138 [157]. I have 
screened for constructs around this predicted winged helix but have not obtained 
soluble protein so far. I have also tried expressing constructs in combination with τ91, 
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based on the cross-links and consistent with a previous study (see also Introduction, 
1.3.6). Identifying the minimal B-box binding region could allow for analysis by X-ray 
crystallography, perhaps by co-crystallisation of the minimal domain with the B-box 
sequence. Alternatively, it could be possible to covalently cross-link TFIIIC to the tDNA 
by UV, in order to identify the region of TFIIIC that remains bound (after extensive 
washing and digestion) by mass spectrometry as has been reported for RNA-binding 
proteins [158]. Further work will be required in order to definitively answer the 
question that leads this section.  
 
3.6.2 What is the role of the other domains within τ138? 
The eWH domain and 1-179 fragments did not bind DNA, as shown by EMSA. However, 
as these are isolated domains, one cannot conclude that they do not bind DNA in vivo. 
Perhaps the eWH domain and/or 1-179 bind DNA in combination with each other, or 
other winged helix domains present in the N terminus. They may also mediate protein-
protein interactions. A structure of a tandem array of winged helix domains, 
interestingly extended winged helix domains, has been reported. Lefèvre et al. 
determined the crystal structure of hRPC62 (the human homologue of the yeast Pol III-
specific subunit C82) which contains four eWH domains arranged around a coiled-coil 
[50]. The eWH domains were shown to bind ssDNA, dsDNA and bind other subunits of 
Pol III. The authors propose that hRPC62 acts as an ‘adaptor platform’ within the 
context of the Pol III PIC. Such a situation could occur for τ138, particularly as many 
intra cross-links occur between the N-terminal predicted winged helix domains. An 
intriguing hypothesis is that the τ138 winged helix domains could stabilise the 
transcription bubble transiently before elongation proceeds, with individual winged 
helix domains contributing low affinity interactions with protein and DNA partners. It 
may also be possible that the winged helix domains surrounding the possible B box 
binding domain help to stabilise B box recognition.  
Finally, what is the role of the predicted HMG boxes at the N and C termini? A very 
recent bioinformatics study and previous work has revealed that these two domains 
are very well conserved [103, 157]. This ~75 amino acid domain of three α-helices 
often binds kinked, or non B-type DNA [156]. It is possible that these HMG boxes 
unwind the promoter DNA, perhaps combining with the winged helix domain for 
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specificity. A structure of the 1-179 fragment would be of some benefit here as it 
contains a predicted HMG box and a winged helix domain. Crystals have been obtained 
but the structure remains unsolved (Section 3.4.2). Further screening of crystallisation 
conditions will be required to produce crystals that produce an interpretable 
diffraction at sufficiently high resolution.  
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 Results - Producing Recombinant TFIIIC 4.
The work in this chapter describes efforts to produce recombinant TFIIIC complex for 
structural and functional studies. The work presented uses the MultiBac method [159] 
in order to produce the complex in insect cells (Spodoptera frugiperda). I present 
purifications of recombinant τA subcomplex and recombinant TFIIIC holo-complex.  
 
 
Figure 4.1 The time required for endogenous TFIIIC purification. Boxed text is taken from Figure 2.1 and 
indicates the major steps taken during endogenous TFIIIC purification. 
 
Our previous work on the full TFIIIC complex has required the purification of this 
protein endogenously from yeast using a TAP-tag strategy. Due to the low abundance 
of TFIIIC in yeast cells, as confirmed by proteomic studies [160, 161], the yield is very 
low (~250 µg of TFIIIC per 150 L yeast culture). As a consequence, the production of 
recombinant TFIIIC would be a significant step in increasing our workflow and allowing 
us to address the types of questions that rely on large amounts of purified protein.  
 
4.1 MultiBac and polyproteins 
In collaboration with the Berger group at EMBL Grenoble, I utilised the MultiBac 
system in efforts to produce the τA and τB subcomplexes and ultimately TFIIIC 
recombinantly in insect cells. The protocols included in this chapter are based on the 
Handbook ‘Eukaryotic Expression Facility at EMBL Grenoble’ from Frederic Garzoni and 
Imre Berger, and on published protocols [159, 162] (see also Materials and Methods, 
6.3). The MultiBac system utilises fluorescent proteins to analyse protein expression 
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and virus performance in order to improve reproducibility and provide a faster means 
of assessing successful protein expression. A yellow fluorescent protein (YFP) is 
encoded in the DNA (Bacmid) of the generated virus as a marker for virus 
performance. Another fluorescent protein (e.g. cyan fluorescent protein, CFP) is also 
present at the C-terminus of the open reading frame to assess protein expression 
levels. When both fluorescence levels reach a plateau (i.e. maximal expression level of 
protein has been reached) the cells can be harvested and the purification proceeds 
(Figure 4.2). For τA, a novel specific polyprotein strategy was used. Specifically, the 
genes for each subunit are contained within the same open reading frame, and 
expression is under the control of one promoter. This strategy allows stoichiometric 
expression of each subunit from the complex. The sequences for each subunit are 
separated by TEV protease-cleavable sites, with the TEV protease-coding gene also 
expressed within the same open reading frame (Figure 4.2). 
 
 
Figure 4.2 Using MultiBac for recombinant τA production. Left, the EMBacY Bacmid DNA with the YFP 
protein and the Tn7 site for integration of the polyprotein construct highlighted. Figure modified from 
[159]. The τA polyprotein is indicated underneath the Bacmid with the encoded proteins, including TEV 
protease and CFP.  Right, monitoring the YFP and CFP values over the course of an infection allows 
optimal harvesting time for cells.  
 
4.2 Recombinant production of τA 
Cloning of constructs was carried out by Christoph Bieniossek, in the Berger group at 
EMBL Grenoble. The τA polyprotein showed most promise in initial expression trials 
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and so I focused on this subcomplex first. Viruses were generated as described in 
Materials and Methods, 6.3.1.  
 
4.2.1 Expression and purification of τA 
The reader is referred to Materials and Methods for full details of expression and 
purification protocols. Typically, 6 L of Sf21 insect cells were infected with V1 virus at a 
dilution of 1 in 10000. When YFP/CFP levels had plateaued the cells were harvested for 
purification. The τA subcomplex was isolated by means of a 10x-histidine tag on the 
τ95 subunit. Soluble lysate was circulated for several hours on a TALON nickel affinity 
column (Clontech) in order to achieve maximum yield yet still with high purity. The 
eluted complex can be seen in Figure 4.3.  
 
 
Figure 4.3 Pull-down of τA subcomplex from insect cells. 12% SDS-PAGE of histidine-eluted τA 
subcomplex. Note the two bands present for τ131 and the double band of TEV protease. * = Sf21 
endogenous protein (determined by mass spectrometry).  
 
All bands were analysed and identified by the Mass Spectrometry Core Facility at EMBL 
Heidelberg. It can be observed that the τ131 subunit degrades readily into a lower 
molecular weight species (~10-20 kDa smaller). The τ95 and τ55 subunits appear not to 
be affected by degradation. A double band, which was identified as TEV protease, is 
also visible. The TEV protease is histidine-tagged and so would be pulled down in 
addition to the complex.  
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Subsequently, the complex was injected onto a Superose 6 gel filtration column 
(GE Healthcare) in order to test for aggregation. As can be seen in Figure 4.4A, the 
complex elutes a single peak, indicating a mono-disperse sample. The elution position 
corresponds approximately to the correct molecular weight of ~250 kDa.  
 
 
Figure 4.4 Analytical Gel Filtration of τA. (A) The sample was injected onto a Superose 6 10/300 GL 
column (GE Healthcare) and elution position analysed. Positions of known molecular weight standards 
are indicated at 670 kDa and 158 kDa. (B) 12% SDS-PAGE showing elution peak. * = unidentified band.  
 
Figure 4.4B shows the elution peak fractions run on SDS-PAGE. The degradation of 
τ131 is still evident, yet the bands appear to migrate together as part of the complex, 
rather than eluting at separate positions distinct from the rest of τA. It could be that 
the cleaved TPRs of τ131 remain attached within the τA subcomplex, thus causing their 
co-migration. A band at approximately 25 kDa is indicated on Figure 4.4B. Although 
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mass spectrometry could not confirm the identity of this species, it is probably a 
degradation band of τ131, owing to its co-migration behaviour with the τA 
subcomplex.  
In summary, a quite substantial yield of τA can be purified from insect cells (~2-
5 mg from 6 L), albeit with degradation of the τ131 subunit.   
 
4.2.2 Functional characterisation of τA 
I first tested whether the τA subcomplex could bind DNA by EMSA (Figure 4.5 and 
Materials and Methods, 6.3.4). The subcomplex could bind to a 256 base-pair tDNA 
oligonucleotide at a concentration of 2-4 µM.  
 
 
Figure 4.5 EMSA experiment of τA binding to a double-stranded DNA 256bp tDNAGlu oligonucleotide. 
Top arrow indicates the shifted τA-DNA complex and the lower arrow indicates free DNA. C = control 
experiment (no protein added). 
 
Next, I investigated the architecture of the τA subcomplex. Chemical cross-linking 
coupled with mass spectrometry was performed in collaboration with the Beck group 
at EMBL Heidelberg. The procedure has been discussed before and further details can 
be found in Materials and Methods, 6.1.2. There are similarities and differences when 
comparing the cross-links obtained for TFIIIC with the cross-links within isolated τA 
(Figure 4.6).  
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Figure 4.6  Comparing chemical cross-linking of isolated τA and as part of TFIIIC. (A) Chemical cross-
linking map of isolated τA. Subunits are represented as bars. Protein length is labelled at the C-terminus. 
Domains of which crystal structures are available are highlighted. τ55 and τ95 Dim. = τ55 and τ95 
dimerisation domains; DBD = DNA-binding domain; HPD = histidine phosphatase domain. Shaded red 
boxes on τ131 indicate predicted TPRs.  Inter cross-links are depicted by lines connecting different 
subunits. Intra cross-links are depicted by arcs which connect residues within the same subunit. (B) 
Comparison with the τA cross-links obtained from holo-TFIIIC. Figure modified from Figure 3.12. 
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In detail, cross-links are obtained between the τ95 and τ55 dimerisation domains for 
both TFIIIC and τA. Furthermore, there are cross-links obtained between τ95 and the 
predicted TPRs of τ131 in the C-terminus in both cases. In τA alone, two cross-links 
appear between τ95 and the TPR array of τ131 (which would be predicted based on 
pull-down experiments of human homologues of τ95 and τ131 [88]) but these are not 
observed with cross-linking of TFIIIC. Furthermore, there are cross-links between τ55 
and τ131 in the isolated τA subcomplex that are not observed in TFIIIC. Most strikingly, 
there are many more intra cross-links obtained within τ95 and τ131 for τA alone (see 
Section 4.4.1). 
In summary, EMSA and cross-linking suggest that the recombinant τA is able to 
bind to DNA and possesses a similar architecture as in the context of TFIIIC. However, 
owing to the degradation of τ131 and the poor appearance of the subcomplex on 
negative stain electron microscopy grids (data not shown), I opted not to pursue 
structural characterisation of τA, but to focus on purification of the full TFIIIC complex. 
 
4.3 Recombinant production of TFIIIC 
A co-infection strategy was attempted for recombinant production of TFIIIC, using τA 
virus described in the previous section and a τB virus. The fluorescence strategy could 
still be employed, as the τB polyprotein is fused to mCherry at the C-terminus, thus 
expression of both subcomplexes can be monitored. In initial tests, Sf21 insect cells 
were infected with V1 virus of both τA and τB at a dilution of 1 in 5000. When 
YFP/CFP/mCherry levels had plateaued the cells were harvested for purification, see 
Materials and Methods, 6.3.3. I had observed previously when attempting to purify the 
τB subcomplex alone, that expression was significantly lower than for τA (data not 
shown). Therefore, I opted to purify the complex by means of the CBP tag on the τ91 
subunit of the τB subcomplex, in order to enhance the recovery of τB subunits. The 
soluble lysate was incubated with CBP resin for 2 hours at 4°C. Figure 4.7A shows the 
eluted complex.   
All six subunits of the TFIIIC complex were successfully isolated by this 
purification. The τ60, τ91 and τ138 subunits of τB are over-represented owing to the 
presence of the CBP tag on τ91. The complex is highly pure after this one-step 
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purification and was immediately injected onto a Superose 6 gel filtration column (GE 
Healthcare) to assess for mono-dispersity and aggregation (Figure 4.7B). 
 
 
Figure 4.7 Recombinant TFIIIC can be purified from insect cells. (A) 12% SDS-PAGE of CBP-eluted TFIIIC 
subcomplex. M = marker; FT = flow-through; W1 = wash 1; HS = high salt wash; W2 = wash; E1 = elution 
1; E2 = elution 2. See Materials and Methods (6.3.3) for details. (B) Analytical gel filtration of TFIIIC. The 
sample was injected onto a Superose 6 10/300 GL column (GE Healthcare) and elution position analysed. 
Positions of known molecular weight standards are indicated at 670 kDa and 158 kDa. The positions of 
the void peak and peak 1 (P1) and peak 2 (P2) are indicated (see main text for details). (C) A silver-
stained SDS-PAGE of a P1 fraction. 
 
There were three peaks observed during the gel filtration run. The first peak 
corresponded to the void volume and, although not displayed on the chromatogram in 
Figure 4.7B, showed a high 260 nm absorbance reading, indicating that this species 
was most likely DNA contamination, as no protein was visible by SDS-PAGE (data not 
shown). The first peak, P1, corresponded to the TFIIIC complex and eluted at the 
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expected molecular weight of ~520 kDa. Analysis by SDS-PAGE revealed the presence 
of all 6 subunits (Figure 4.7C). The second peak, P2, corresponded to the τ60-τ91 dimer 
and probably reflects an excess of these subunits based on the CBP tag location on τ91 
(data not shown). In summary, the purification protocol can produce recombinant, 
mono-disperse TFIIIC.  
 
4.4 Discussion 
This chapter has detailed efforts to produce TFIIIC recombinantly using the MultiBac 
expression system in insect cells. A bottleneck for structural and functional studies on 
TFIIIC has been the very low yield of TAP-tagged protein from yeast. Early results look 
promising but will require further work in order to produce the desired yield. The work 
has also provided insight into the τA and τB subcomplexes and highlighted once again 
the need for a τ131-τ138 link which was characterized in the earlier chapters.  
 
4.4.1 τ131 and τ138  degrade in the isolated τA and τB subcomplexes 
The two DNA-binding subcomplexes of TFIIIC have been defined as τA and τB, with τA 
consisting of the subunits τ131, τ95 and τ55, and τB consisting of the subunits τ138, 
τ91 and τ60. This definition was used when designing our MultiBac TFIIIC constructs. As 
a short note, a full TFIIIC polyprotein was also synthesised but never showed 
detectable expression. The purification of the τA subcomplex that I have presented in 
this chapter shows that the trimeric τA complex can be expressed, pulled down and 
stays stably associated on gel filtration. However, the τ131 degrades rapidly and is 
clearly unstable in the absence of a τB subunit or subunits. This stabilisation is most 
likely mediated through τ138, as I have shown before that these two subunits directly 
interact. The larger number of intra cross-links observed within τ131 in the isolated τA 
subcomplex may be a consequence of this degradation, but is most likely due to the 
increased flexibility of τ131 in the absence of τB subunits or because these residues 
would normally interact directly with τB subunits in the context of TFIIIC. 
Unfortunately, I could not purify sufficient quantity of the τB subcomplex alone for 
similar cross-linking studies on the isolated τB subcomplex. It was observed that the 
largest subunit τ138 readily degraded, indicating that the τ60-τ91 scaffold is not 
sufficient for τ138 stabilisation. Again, based on my former findings, the τ131 subunit 
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of τA would probably be required for stabilisation of this subunit. In the context of 
recombinant TFIIIC, no degradation is observed for the τ131 and τ138 subunits, 
indicating that the combination of τA and τB is required for stabilisation of the τ131 
and τ138 subunits.  
 
4.4.2 Optimisation of recombinant TFIIIC purification 
As shown in Figure 4.7, a recombinant TFIIIC complex can be produced in insect cells 
by using the protocols I have established. This procedure significantly cuts the time, 
effort and cost associated with purifying endogenous TFIIIC from yeast (Figure 4.8).  
 
 
Figure 4.8 Comparing endogenous and recombinant purification of TFIIIC. (A) Overview of the 
endogenous TFIIIC purification as shown in Figure 4.1. (B) Overview of the recombinant TFIIIC 
purification. 
 
In addition, it will allow the specific truncation or deletion of subdomains and 
introduction of point mutants that would lead to lethality in yeast cells as TFIIIC is an 
essential macromolecular complex.  However, it is also apparent at this stage that 
producing large amounts of TFIIIC for structural and functional studies is still tricky. 
There is a significant difference in expression levels when comparing the τA and τB 
subcomplexes. It is not clear why the τB construct expresses so poorly but may be due 
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to the differences in vector backbone (pKL as opposed to pPBac for τA). One could try 
different vectors for τB expression and/or change the affinity tag on τB to improve the 
yield, although clearly the CBP tag allows the purification of a highly pure sample. 
Tagging another subunit may also be appropriate. τ60 for instance, at the C-terminus, 
has been shown to work in our TAP-tag purifications of TFIIIC. The results presented 
here are from relatively small-scale experiments (500 mL of insect cell culture) and so 
can be scaled up to produce larger quantities of material, but clearly resolving the 
issue with expression of τB is of paramount importance. 
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 Outlook and Final Discussion 5.
In this chapter, I will draw some overall conclusions based on the results and 
discussions presented in the previous chapters. I will also provide some future 
directions and perspectives for this exciting research field. 
 
5.1 Linking the τA and τB subcomplexes of TFIIIC 
The major finding of this thesis is the identification of a high-affinity interaction 
between the largest τA subunit, τ131, and the largest τB subunit, τ138. This is a novel 
finding which has been confirmed biochemically, biophysically using isolated proteins, 
and in the context of the entire TFIIIC complex. These two subunits could indeed form 
the flexible linker between the τA and τB subcomplexes, that has remained a molecular 
mystery for the last decades. Complementing in vivo mutational experiments in yeast 
are ongoing, in order to assess whether this link is the major connection between the 
τA and τB subcomplexes. 
Another question regards the definition of the τA and τB subcomplexes and 
whether or not they actually exist in vivo. The concept of τA and τB stemmed from 
early electron microscopy studies and proteolysis experiments, and was further 
defined by biochemical and genetic experiments. However, for yeast TFIIIC it has been 
shown that the complex cannot be chromatographically separated into the two 
subcomplexes without proteolysis, suggesting that the two subcomplexes are 
extensively stabilised by each other. It is also clear from my in vitro purification that 
the τ131 subunit is not stable in the context of the subcomplex τA alone. The picture 
becomes more complicated with additional evidence that suggests the τ95-τ55 
subcomplex exists independently from holo-TFIIIC [79]. Further structural work will be 
required to understand exactly which subunits or parts of subunits constitute the τA 
and τB subcomplexes and whether this definition will remain relevant.  
 
5.2 τ131 - a hub for PIC formation 
The TPR array of τ131 not only links τA and τB via τ138, it also provides a platform for 
the binding of τ95 [88], TFIIIB [109] and Pol III [119], as discussed in the Introduction. I 
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confirmed that Bdp1 binds the TPR array by GST pull-down experiments and that the 
site overlaps with that of τ138 (Figure 2.22 and Figure 2.23). It is apparent that both 
arms of the TPR array are required for the binding of the Brf1 and Bdp1 subunits of 
TFIIIB [87], and that some degree of conformational flexibility must exist. The flexibility 
of τ131 has indeed been demonstrated, as photo cross-linking studies revealed that 
τ131 adopted different positions on the tRNA gene upon binding of TFIIIB [163]. The 
temperature factors displayed in Figure 2.14B also indicate flexibility at the N and C 
termini of the structure. Furthermore, the point mutants I have identified that reduce 
τ138 and Bdp1 binding are situated between the two arms and could suggest that 
changes to the architecture of the TPR array are important for ligand binding. The TPR 
array of τ131 may thus act as a flexible scaffold at which various subunits involved in 
Pol III transcription could assemble. Figure 5.1 displays the sequential events that 
could occur at the τ131 TPR array during pre-initiation complex (PIC) formation and is 
based on the model proposed in [87] and on the findings I have presented in this 
thesis.  
 
 
Figure 5.1 The TPR array as a hub for PIC formation. The TPR array is coloured according to binding 
regions of the highlighted subunit. 
 
The TPRs would, in a first step, stabilise the disordered regions of τ95 and τ138, 
perhaps supporting A box and B box binding. With TFIIIC bound at the promoter 
elements, TFIIIB can then be assembled. Brf1 and TBP would be recruited first, 
consistent with the literature, with Brf1 binding at various points over both of the 
arms. τ138 and τ95 would be displaced, allowing interaction with other components of 
the PIC. In a final step, Bdp1 is recruited and stabilises the TFIIIB-TFIIIC-DNA complex 
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[43], allowing recruitment of Pol III, with subunits ABC10α and RPC53 contacting the 
TPR array. Access to these overlapping sites would require conformational flexibility 
and time-resolved binding of the various subunits. 
In order to confirm the proposed series of events, an integrated structural biology 
approach will be required. This will require the combination of high resolution 
structures of various subcomplexes of the PIC together with cryo-electron microscopy 
reconstructions of larger assemblies of TFIIIC, TFIIIB and Pol III. This could be coupled 
with photo chemical cross-linking studies that have already been reported [118] and 
additional lysine-lysine cross-linking in order to arrive at a model for PIC formation.  
 
5.3 Towards a quasi-atomic model of TFIIIC 
An ongoing research aim is the elucidation of the molecular architecture of TFIIIC. The 
work in this thesis will strongly support this aim. Firstly, the high resolution structure of 
an extended winged helix domain of τ138 that I have presented could be used as a 
model for the remaining winged helix domains within this subunit (Figure 5.2). 
Secondly, the characterisation of an interface between the τ138 and τ131 subunits will 
provide additional restraints with which to model the interface between the 
subcomplexes τA and τB. Finally, the cross-links obtained for TFIIIC will also act as 
distance restraints for modelling the entire complex. In order to arrive at a consistent 
model for TFIIIC architecture, an integrated structural biology approach will again be 
needed. Ideally, a cryo electron microscopy reconstruction of the entire complex 
would be obtained, within which one can confidently position the high resolution 
structures (guided by cross-linking and biochemical data). One could use all these 
restraints to model the complex and then validate the resulting modelled interfaces in 
vitro or in vivo by mutations.  
One of the big challenges for arriving at a TFIIIC model is the availability of the 
TFIIIC protein itself for structural and functional studies. As highlighted in this thesis, 
the purification of endogenous TFIIIC results in a very low yield of protein, after an 
expensive and time-consuming procedure. Producing TFIIIC recombinantly would be of 
huge benefit for the project and I have presented work that, with some optimisation 
still required, should provide a stable protocol for producing sufficient amounts of this 
protein complex in insect cells for future studies.  
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Figure 5.2 A model for TFIIIC. (A) Current crystal structures of TFIIIC and their approximate positions 
within TFIIIC (note the τ55 HPD structure is omitted for clarity). Predicted C-terminal TPRs of τ131 and 
predicted winged helix domains of τ138 are included. The G349E mutant is highlighted in eWH3. Arrows 
represent cross-links that have been obtained and could indicate interactions. (B) Models of N-terminal 
winged helix domains of τ138 with surface electrostatic representations. The eWH domain is included 
for comparison. The models were generated using MODexplorer [164, 165].  
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This thesis has presented new information about the link between the τA and τB 
subcomplexes of TFIIIC. In addition, cross-linking studies together with crystallography 
and biochemistry have provided novel insights into the architecture of this intriguing 
protein complex (Figure 5.2). The τA and τB subcomplexes are linked through 
interactions between τ131 and τ138. Cross-linking also indicates a role for τ95. 
Questions remain over how the remaining TPRs of τ131 function within TFIIIC: cross-
linking indicates they bind τ95. Questions also remain over the interaction of τ91 with 
the winged helix domains of τ138 in the context of B box recognition. Models of the 
remaining N-terminal winged helix domains of τ138 have been generated using 
MODexplorer [164, 165]. The third predicted winged helix is likely to also be an 
extended winged helix based on the structure predictions and so was modelled on the 
eWH I have solved. Each of the modelled winged helix domains contains a large basic 
patch which could bind nucleic acids – although I have demonstrated that WH1 (as 
part of the 1-179 construct) and the eWH do not bind tDNA. A combinatorial binding of 
several of the winged helix domains may thus be required for B box binding as has 
been discussed earlier. Future work will need to bring the remaining unsolved parts of 
this protein together in order to fully understand its architecture and function in type 2 
promoter recognition.  
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 Materials and Methods 6.
 
6.1 Results - linking τA and τB 
6.1.1 Yeast TFIIIC fermentations 
Fermentations for TAP-tagged TFIIIC from S. cerevisiae were performed by Emmanuel Poilpre  
(EMBL protein expression and purification core facility) using a 30 litre fermenter. I also 
performed two 150 litre fermentations. The strain used – YPL007C – contains a TAP-tag on the 
τ60 (TFC8) subunit and was provided by the Anne-Claude Gavin group at EMBL Heidelberg.  
 
6.1.2 Chemical cross-linking coupled with mass spectrometry 
The following protocol was kindly provided by Alexander von Appen, a PhD student in the 
Martin Beck Group at EMBL Heidelberg. 
30 μg (1 μg/μl) of purified TFIIIC complex was cross-linked by addition of an iso-stoichiometric 
mixture of H12/D12 isotope-coded, di-succinimidyl-suberate (DSS, Creative Molecules). Equal 
amounts of cross-linker were added ten times every 4 min to a final concentration of 2 mM. 
The crosslinking reactions were allowed to proceed for 40 min at 37°C and quenched by 
addition of ammonium bicarbonate to a final concentration of 50 mM for 10 min at 37°C. 
Cross-linked proteins were denatured using urea and Rapigest (Waters) at a final 
concentration of 4 M and 0.05% (w/v), respectively. Samples were reduced using 10 mM DTT 
(30 min at 37°C) and cysteines were carbamidomethylated with 15 mM iodoacetamide (30 min 
in the dark). Protein digestion was performed first using 1:100 (w/w) LysC (Wako Chemicals 
GmbH, Neuss, Germany) for 3.5 hours at 37°C then finalised with 1:50 (w/w) trypsin (Promega 
GmbH, Mannheim, Germany) overnight at 37°C, after the urea concentration was diluted to 
1.5 M. Samples were then acidified with 10% (v/v) TFA and desalted using MicroSpin columns 
(Harvard Apparatus) following the manufacturer’s instructions. Cross-linked peptides were 
enriched using size exclusion chromatography (SEC) as described by [143]. In brief, desalted 
peptides were reconstituted with SEC buffer (30% (v/v) ACN in 0.1% (v/v) TFA) and 
fractionated using a Superdex Peptide PC 3.2/30 column (GE) on a Ettan LC system (GE 
Healthcare) at a flow rate of 50 µl/min. Fractions eluting between 1 and 1.5 ml were 
evaporated to dryness and reconstituted in 50 µl 5% (v/v) ACN in 0.1% (v/v) FA. Between 2 and 
10% of the amount contained in the collected SEC fractions were analysed by liquid 
chromatography (LC)-coupled tandem mass spectrometry (MS/MS) using a nanoAcquity UPLC 
system (Waters) connected online to LTQ-Orbitrap Velos Pro instrument (Thermo). Peptides 
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were separated on a BEH300 C18 (75 mm x 250 mm, 1.7 mm) nanoAcquity UPLC column 
(Waters) using a stepwise 60 min or 120 min gradient between 3 and 85% (v/v) ACN in 0.1% 
(v/v) FA. Data acquisition was performed using a TOP-20 strategy where survey-MS scans (m/z 
range 375-1,600) were acquired in the Orbitrap (R = 30,000) and up to 20 of the most 
abundant ions per full scan were fragmented by collision-induced dissociation (normalised 
collision energy = 40, activation Q = 0.250) and analysed in the LTQ. In order to focus the 
acquisition on larger cross-linked peptides, charge states 1, 2 and unknown were rejected. 
Dynamic exclusion was enabled with repeat count = 1, exclusion duration = 60 s, list size = 500 
and mass window ± 15 ppm. Ion target values were 1,000,000 (or 500 ms maximum fill time) 
for full scans and 10,000 (or 50 ms maximum fill time) for MS/MS scans. All the samples were 
analysed in technical duplicates. To assign the fragment ion spectra, raw files were converted 
to centroid mzXML using the Mass Matrix file converter tool and searched using xQuest [166] 
against a FASTA database containing sequences of the cross-linked proteins. Posterior 
probabilities were calculated using xProphet [166] and results were filtered accordingly: FDR = 
0.05, min delta score = 0.95, MS1 tolerance window of 4 to 7 ppm, ld-score > 25. 
 
6.1.3 Cloning of τ138 constructs  
Codon optimised constructs of S. cerevisiae τ138 were cloned into pETM30, which introduces 
an N-terminal, TEV protease-cleavable, 6x-histidine GST affinity tag as described below. 
(i) Primer Design  
Primers were designed so as to generate a polymerase chain reaction (PCR) fragment that 
included the desired coding sequence, preceded by an NcoI restriction enzyme site at the 5’ 
end and an Acc65I restriction site at the 3’ end. Overhang sequences at the 5’ and 3’ ends were 
included to ensure an efficient restriction enzyme cleavage in a later step. Melting 
temperatures (Tm) for both primers were kept as close as possible and were designed to be 
between 60 and 65°C.  
(ii) PCR and PCR purification 
PCR reactions were set up as outlined below: 
Reagent Volume (Final Concentration) 
H2O 37.9 µL 
5x HF buffer  10 µL 
10 mM dNTP mix 1 µL (200 µM of each dNTP) 
Template1 0.1 µL (1-10 ng) 
Fw Primer 0.25 µL (0.5 µM) 
Rv Primer 0.25 µL (0.5 µM) 
Phusion2 Polymerase  0.5 µL 
1 τB MultiBac Vector  2 Phusion High Fidelity DNA Polymerase (Finnzymes) 
99 
 
The reaction was mixed thoroughly and then placed into a PCR machine (Eppendorf 
Mastercycler Gradient). The reaction was carried out as follows (and as recommended by the 
manufacturer of Phusion Polymerase). Note that the table below outlines a protocol that was 
generally applicable for my cloning, occasionally changes to annealing temperature or 
extension times were required. 
Step Temperature  Time Cycles 
Initial Denaturation 98°C 30 s 1 
Denaturation 98°C 10 s 35 
Annealing Primer Tm -5°C 30 s 
Extension 72°C 30 s per kilobase 
Final Extension 72°C 5 min 1 
 
5 µL of the PCR product was analysed on a 1% agarose gel to assess purity. If pure, the 
remaining PCR product was purified using the Qiaquick PCR Purification Kit (Qiagen). In the 
case of contaminant bands, the remaining PCR product was ran on a 1% agarose gel and 
purified using the Qiaquick Gel Extraction Kit (Qiagen). In both scenarios the final PCR product 
was eluted in 30 µL H2O with a final concentration of usually 100 ng/µL. 
(iii) Restriction Digest 
Restriction double digests were set up as follows, with buffer requirements determined by the 
use of the NEB double digest online tool (www.neb.com).  
Reagent Volume 
H2O 12.5 µL 
PCR Product (100ng/ µL) 30 µL 
NEB 3 reaction buffer 5 µL 
BSA (100x) 0.5 µL 
NcoI1 1 µL 
Acc65I1 1 µL 
1New England Biolabs 
 
The reaction was mixed thoroughly and restriction digests were incubated at 37°C overnight. 
The reactions were then analysed by running them on a 1% agarose gel. A single band 
corresponding to the digested product was cut from the gel and the DNA ‘insert’ was extracted 
using the Qiaquick Gel Extraction kit (Qiagen). 5 µg of pETM30 vector was digested in parallel 
by the same methods. Both vector and insert were eluted in 30 µL H2O for ligation. The vector 
was dephosphorylated (to reduce the chances of re-ligation without insert) using Antarctic 
Phosphatase (New England Biolabs) for 1 hour at 37°C before inactivation at 65°C for 15 mins. 
(iv) Ligation, Transformation and Positive Clone Selection. 
Ligation reactions were set up as follows. A Molar ratio of 1:3 (vector:insert) was desired. As 
vector stock concentration was constant at 100 ng/µL and insert concentrations were in the 
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range of 20-40 ng/µL a ratio of 1 µL vector and 3 µL insert was usually sufficient for a 
successful ligation reaction, based on the base pair sizes of the pETM30 vector and my inserts. 
DNA concentrations were always checked and adjusted however if this was not the case. 
Reagent Volume (µL) 
H2O 4 
pETM30 Vector (100 ng/µL) 1 
DNA Insert (20-40 ng/µL) 3 
T4 Ligase buffer (10x) 1 
T4 DNA Ligase1 1 
1New England Biolabs 
 
A control ligation was also carried out, whereby no insert was included. Ligation reactions 
were mixed thoroughly and incubated overnight at room temperature. 2 µL of ligation and 
control reaction were then transformed into 50 µL XL1 Blue electrical competent cells 
(Stratagene) before incubation for 1 hour at 37°C in 950 µL SOC media. 200 µL of cells were 
then plated out on to LB-Agar plates containing the antibiotic kanamycin (50 µg/mL) of which 
cells carrying the ligated pETM30 vector would have resistance to. Plates were incubated 
overnight at 37°C. A successful ligation can initially be assessed by the presence of colonies on 
the ligation plate but none, or very few on the control plate. Colonies were picked and 
inoculated in 2 mL of LB medium containing kanamycin and incubated overnight at 37°C. DNA 
was purified using the Qiaprep Spin miniprep kit (Qiagen) and a small aliquot tested by 
restriction digest and agarose gel analysis for the presence of vector and insert. Positive clones 
were then sent for sequencing (GATC Biotech) to confirm the fidelity of the insert.  
 
6.1.4 Expression and purification of GST-tagged τ138 constructs  
Vectors were transformed into BL21 (DE3) Gold E. coli cells (Invitrogen) and plated out on LB-
Agar plates containing kanamycin (50 µg/mL), and were then incubated overnight at 37°C. 50 
mL pre-cultures, supplemented with kanamycin, were grown in TB media till an OD600 of 0.8. 
12 L of TB media supplemented with kanamycin were then inoculated with the pre-culture and 
grown at 37°C until an OD600 of 0.8. Cells were induced overnight at 18°C with 0.5 mM IPTG. 
Lysis and purification was the same as for the τ131-τ138 complex (Section 6.1.8), with the 
exception that the GST tags were not cleaved and so after elution the proteins were 
immediately injected onto a Superdex S200 prep grade gel filtration column (GE Healthcare). 
The eluted proteins were analysed by SDS-PAGE and then concentrated.   
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6.1.5 Expression and purification of τ138 ‘641-681’ and ‘641-693’ 
The constructs were codon-optimised and were expressed in BL21 (DE3) Gold E. coli cells 
(Invitrogen) using the same strategy as described in Section 6.1.8. The cells were harvested by 
centrifugation and resuspended in lysis buffer (5% glycerol, 50 mM Tris pH 7.5 (at 4°C), 500 
mM NaCl, 20 mM imidazole, 4 mM MgCl2, Complete EDTA-free protease inhibitor cocktail (1 
tablet/100 mL – Roche), DNase1 (Roche), 2 mM β-mercaptoethanol). After lysis and 
centrifugation (Section 6.1.8) the soluble fraction was incubated with 1 mL nickel-NTA agarose 
resin (Qiagen) for 1 hour at 4°C. The resin was packed into a 10 mL disposable column 
(ThermoScientific) and the flow-through collected. The resin was washed with 20 column 
volumes of binding buffer (50 mM Tris pH 7.5 (at 4°C), 300 mM NaCl, 20 mM imidazole, 2 mM 
β-mercaptoethanol), 20 column volumes of high salt buffer (50 mM Tris pH 7.5 (at 4°C), 1 M 
NaCl, 20 mM imidazole, 2 mM β-mercaptoethanol) and then 20 column volumes of binding 
buffer again. The protein was eluted with 5 column volumes of elution buffer (50 mM Tris pH 
7.5 (at 4°C), 300 mM NaCl, 250 mM imidazole, 2 mM β-mercaptoethanol). The eluate was 
analysed by SDS-PAGE and then dialysed with TEV protease (EMBL protein expression and 
purification core facility) overnight, in a ratio of 1 µg TEV protease to 100 µg eluate, in 2 L of 
binding buffer. The resin was stored in elution buffer overnight. The eluate was then re-
incubated with the nickel resin that had been cleaned with H2O and re-equilibrated in binding 
buffer and incubated at 4°C for 1 hour. The resin was re-applied to the column and the flow-
through containing the cleaved protein was collected. The flow-through was then applied to a 
5 mL HiTrap SP HP column (GE Healthcare) that had been pre-equilibrated in buffer ‘A’ (50 mM 
Tris pH 7.5 (at 4°C), 50 mM NaCl,  2 mM DTT). The column was washed with 20 column 
volumes of buffer ‘A’, before a gradient of 40 column volumes into buffer ‘B’ was applied (50 
mM Tris pH 7.5 (at 4°C), 1 M NaCl, 2 mM DTT). The proteins eluted as a single peak and were 
analysed by SDS-PAGE before being concentrated. The proteins were then dialysed overnight 
into ITC buffer (20 mM Tris pH 7.5 (at 4°C), 150 mM NaCl, 1 mM β-mercaptoethanol).  
 
6.1.6 GST pull-down experiments 
15 µg of GST-tagged τ138 protein and 900 nM τ131 (123-566) protein were incubated with 25 
µL Glutathione Sepharose 4B beads in pull-down buffer (50 mM Tris pH 7.5 (at 4°C), 150 mM 
NaCl, 1 mM DTT and 0.1 % Tween20) at 4°C for 4 hours. The beads were then washed three 
times with pull-down buffer, before being heated to 100°C in Laemmli sample buffer for 5 min. 
Samples were analysed by SDS-PAGE.  
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6.1.7 Isothermal Titration Calorimetry (ITC) experiments 
ITC was performed using a MicroCal ITC200 System (GE Healthcare). For experiments mapping 
the τ131-τ138 interaction, all samples were dialysed into ITC buffer (20 mM Tris pH 7.5 (at 
4°C), 150 mM NaCl and 2 mM β-mercaptoethanol). The protein concentration in the cell was 
15 µM and the protein concentration in the syringe was 150 µM. Experiments were performed 
at room temperature.   
 
6.1.8 Co-expression and purification of τ131 (123-566) - τ138 (641-693)  
The τ131 (123-566) construct was sub-cloned into the untagged vector pCDF. The vectors were 
co-transformed into p*RARE E. coli cells (Invitrogen) and plated out on LB-Agar plates 
containing kanamycin (50 µg/mL) (pETM30), streptomycin (50 µg/mL) (pCDF) and 
chloramphenicol (33 µg/mL) (p*RARE), and incubated overnight at 37°C. 50 mL pre-cultures, 
supplemented with antibiotics, were grown in TB media till an OD600 of 0.8. 12 L of TB media 
supplemented with antibiotics were then inoculated with the pre-culture and grown at 37°C 
until an OD600 of 0.8. Cells were induced overnight at 18°C with 0.5 mM IPTG. Cells were 
harvested the next day by centrifugation and resuspended in the appropriate volume of lysis 
buffer (5% glycerol, 50 mM Tris pH 7.5 (at 4°C), 150 mM NaCl, 2 mM MgCl2, Complete EDTA-
free protease inhibitor cocktail, DNase1 (Roche), 2 mM DTT) for the weight of the pellet. All 
following steps were carried out at 4°C. The cells were lysed by two rounds of homogenisation 
(Avestin Emulsiflex-C3). The lysate was cleared by centrifugation at 20,000 rpm for 1 hour in a 
JA 25.50 Rotor (Beckmann).  The soluble fraction was then incubated overnight on an Aekta 
PRIME using a GST preparative FF 16/60 column (GE Healthcare) which had been pre-
equilibrated in lysis buffer, at a flow rate of 0.3 mL/min. The next day, the column was 
equilibrated with binding buffer (50 mM Tris pH 7.5 (at 4°C), 150 mM NaCl, 2 mM DTT). When 
the UV absorbance had decreased to baseline, the column was washed with 10 column 
volumes of high salt buffer (50 mM Tris pH 7.5 (at 4°C), 750 mM NaCl, 2 mM DTT). The column 
was then equilibrated with binding buffer until the conductivity had reached baseline. Elution 
was carried out at 1 mL/min using elution buffer (50 mM Tris pH 7.5 (at 4°C), 150 mM NaCl, 10 
mM reduced glutathione, 2 mM DTT). 3 mL Fractions were collected and fractions which 
corresponded to a peak in absorbance were analysed by SDS-PAGE and pooled accordingly. 
The pooled eluate was dialysed together with GST-tagged TEV protease (EMBL protein 
expression and purification core facility) overnight, in a ratio of 1 µg TEV protease to 100 µg 
eluate, in 2 L of binding buffer. The column was washed with H2O, 6 M guanidine 
hydrochloride and then H2O again. The column was then equilibrated with binding buffer in 
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preparation for the second GST-affinity step. After overnight TEV protease cleavage, the eluate 
was circulated over the column at 0.3 mL/min for several hours. The flow-through was 
collected (cleaved protein) and concentrated to 8 mL for gel filtration. Gel filtration was carried 
out using a 320 mL Superdex 200 preparative grade column (GE Healthcare) that had been pre-
equilibrated in gel filtration buffer (20 mM Tris pH 7.5 (at 4°C), 150 mM NaCl, 2 mM DTT). The 
protein was injected using a 10 mL loop. 2mL Fractions were collected and fractions which 
corresponded to a peak in absorbance were analysed by SDS-PAGE. 
 
6.1.9 Selenomethionine-incorporated τ131 (123-566) - τ138 (641-693) expression 
Expression was carried out in BL21 (DE3) Gold (Invitrogen) by feedback inhibition of 
methionine synthesis. This protocol has been established previously in our lab. A 5 mL pre-
culture was grown in LB medium till an OD600 of 0.6. The culture was harvested and the pellet 
was resuspended and washed twice with M9 medium (1x M9 salts1, 2 mM MgSO4, 20% 
glucose, 1 µg/mL thiamine, 1x trace elements2, 0.1 mM CaCl2). 50 mL M9 pre-culture (per litre 
of cells) was grown overnight. Pre-culture was added to 1 L of M9 medium and cells were 
grown till an OD600 of 0.6. Several amino acids were then added to ensure feedback inhibition 
of methionine synthesis. 100 mg/L of lysine, phenylalanine, threonine and 50 mg/L of 
isoleucine, leucine and valine were added. Finally, 50 mg/L selenium-methionine was added. 
The cells were incubated for 20 minutes, before being induced overnight at 18°C with 0.5 mM 
IPTG. Purification of selenomethionine-incorporated τ131 (123-566) - τ138 (641-693) complex 
was as with the native protein (Section 6.1.8). A lower overall yield was obtained in 
comparison to the native complex but sufficient quantities for crystallisation were obtained.  
1M9 salts (10x) – Na2HPO4 (70 g), KH2PO4 (30 g), NaCl (5 g), NH4Cl (5 g). 
2Trace elements – EDTA (5 g), FeCl3 (0.83 g), ZnCl2 (0.084 g), CuCl2x6H2O (0.013 g), CoCl2x6H2O 
(0.010 g), boric acid (0.010 g), MnCl2x6H2O (1.6 mg).  
 
6.1.10 Cloning and purification of τ131 point mutants 
Cloning of the τ131 point mutants was carried out using the QuikChange Lightning Kit (Agilent 
Technologies). The PCR protocol was carried out following the manufacturer’s guidelines. 
Primers introducing the specific point mutations were designed using an online tool 
(https://www.genomics.agilent.com/primerDesignProgram.jsp) from Agilent Technologies. 
After PCR, 1 µL of DpnI was added to each reaction and incubated for 15 min at 37°C in order 
to digest parental template. 10 µL of the DpnI-treated mixture was then transformed by heat-
shock at 42°C into chemically-competent XL10-gold E. coli cells (Agilent Technologies). Cells 
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were then plated out onto LB-Agar plates containing kanamycin (50 µg/mL). Colonies were 
picked and inoculated in 2 mL of LB medium containing kanamycin and incubated overnight at 
37°C. DNA was purified using the Qiaprep Spin miniprep kit (Qiagen). Clones were then sent for 
sequencing (GATC Biotech) to confirm the presence of the mutation. 
 
6.2 Results – structural and functional studies on τ138 
6.2.1 Small-scale expression and purification of τ138 constructs 
Owing to the large number of constructs generated for this project, I tried wherever possible 
to increase the throughput of expression and solubility testing. In each ‘round’ of trials I took 6 
constructs and purified them. I expressed the constructs using 1 L of BL21 (DE3) Gold cells 
(Invitrogen) in TB. Cells were grown at 37°C to an OD600 of 0.8 and expression was induced 
overnight using 0.5 mM IPTG at 18°C. Cells were harvested by centrifugation and re-suspended 
in lysis buffer (5% glycerol, 50 mM Tris pH 7.5 (at 4°C), 500 mM  NaCl, 2 mM MgCl2, Complete 
EDTA-free protease inhibitor cocktail (Roche), DNaseI (Roche), 2 mM DTT). Cells were lysed 
and then centrifuged (Section 6.1.8). The soluble fraction was incubated with Glutathione 
Sepharose 4B resin (GE Healthcare) overnight at 4°C. The next day, the samples were applied 
to a disposable column (ThermoScientific) and the flow-through was collected. The resin was 
washed with 20 column volumes of binding buffer (50 mM Tris pH 7.5 (at 4°C), 150 mM  NaCl, 
2 mM DTT) before elution was carried out with 5 column volumes of elution buffer (50 mM 
Tris pH 7.5, 150 mM NaCl, 10 mM reduced glutathione, 2 mM DTT). Samples were analysed by 
SDS-PAGE.  
 
6.2.2 Expression and purification of τ138 (546-641) 
The codon-optimised sequence encoding for τ138 (546-641) was cloned into pETM30 (Section 
6.1.3) and transformed into BL21 (DE3) Gold E. coli cells (Invitrogen). Cells were plated out on 
LB-Agar plates containing kanamycin (50 µg/mL) and incubated at 37°C overnight. A 50 mL pre-
culture, supplemented with kanamycin was grown in TB till an OD600 of 0.8. 12L of TB 
supplemented with kanamycin was then inoculated with the pre-culture and grown at 37°C 
until an OD600 of 0.8. Cells were induced overnight at 18°C with 0.5 mM IPTG. The cells were 
harvested and resuspended in lysis buffer (5% glycerol, 50 mM Tris pH 7.5 (at 4°C), 500 mM  
NaCl, 20 mM imidazole, 4 mM MgCl2, Complete EDTA-free protease inhibitor cocktail (Roche), 
DNaseI (Roche), 2 mM β-mercaptoethanol). After lysis and centrifugation (Section 6.1.8) the 
soluble fraction was incubated with 2 mL nickel-NTA agarose resin (Qiagen) for 1 hour at 4°C. 
The resin was packed into a 10 mL disposable column (ThermoScientific) and the flow-through 
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collected. The resin was washed with 20 column volumes of binding buffer (50 mM Tris pH 7.5 
(at 4°C), 300 mM NaCl, 20 mM imidazole, 2 mM β-mercaptoethanol), 20 column volumes of 
high salt buffer (50 mM Tris pH 7.5 (at 4°C), 1 M  NaCl, 20 mM imidazole, 2 mM β-
mercaptoethanol) and then binding buffer again. The protein was eluted with 5 column 
volumes of elution buffer (50 mM Tris pH 7.5 (at 4°C), 300 mM NaCl, 250 mM imidazole, 2 mM 
β-mercaptoethanol). The eluate was analysed by SDS-PAGE and then dialysed with TEV 
protease (EMBL protein expression and purification core facility) overnight, in a ratio of 1 µg 
TEV protease to 100 µg eluate, in 2 L of binding buffer. The resin was stored in elution buffer 
overnight. The eluate was then re-incubated with the nickel resin, which had been cleaned 
with H2O and re-equilibrated in binding buffer, and incubated at 4°C for 1 hour. The resin was 
re-applied to the column and the flow-through containing the cleaved protein was collected. 
The flow-through was concentrated to 4 mL for gel filtration. The protein was injected using a 
5 mL loop onto a Superdex 75 preparative column (GE Healthcare) that had been pre-
equilibrated in gel filtration buffer (20 mM Tris pH 7.5 (at 4°C), 150 mM NaCl, 2 mM DTT). 2 mL 
Fractions were collected and fractions which corresponded to a peak in absorbance were 
analysed by SDS-PAGE. 
 
6.2.3 Expression and purification of τ138 (1-179) 
Methods and buffers were exactly the same as for τ138 (546-641). See Section 6.2.2 for details.  
 
6.2.4 EMSA of τ138 (546-641) and τ138 (1-179) 
(i) Labelling of oligonucleotides 
In a first step, the HPLC-purified, 66-base single-stranded (ss) tDNAGlu oligonucleotides 
(forward and reverse -  5’ - CGA TAT AGT GTA ACG GCT ATC ACA TCA CGC TTT CAC CGT GGA 
GAC CGG GGT TCG ACT CCC CGT ATC - 3’) were radioactively labelled. A 10 µL reaction was set 
up which included 3 µg of the oligonucleotide, 10 U/ µL of T4 PNK (New England Biolabs) and 
3000 Ci/mmol of ATPγP32. The reaction was incubated at 37°C for 1 hour. Labelling was 
stopped by incubating the reaction at 95°C for 3 min. A 15% denaturing (8M Urea) SDS-PAGE 
was pre-run for 1 hour at 25 W before samples were loaded and run for approximately 1 hour 
at 25 W. The gel was placed onto plastic film and auto-radiographed to identify labelled 
oligonucleotides. The bands were removed, placed into a 1.5 mL Eppendorf tube and eluted 
with 300 µL elution buffer (0.6 M AcNH4, 1 mM EDTA, 0.1% SDS) overnight. The eluted DNA 
was then precipitated by adding 3 volumes of 100% ethanol and 1 µL of glycogen (20 mg/mL) 
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at -20°C for 30 min. Samples were then centrifuged at 4°C for 20 min, before being 
resuspended in 20 µL H2O.  
(ii) EMSA 
1 µL of labelled 66-base tDNAGlu (forward) in one reaction and 1 µL + 1 µL of labelled 66-base 
tDNAGlu (forward & reverse) in a second reaction were incubated at 95°C for 2 min, thus 
allowing annealing of forward and reverse to double-stranded (ds) DNA. 12 µL of EMSA buffer 
(20 mM Tris pH 7.5 (at 4°C), 150 mM NaCl, 1 mM MgCl2, 2 mM DTT) was added to cool the 
reactions to room temperature. 1 µL of ssDNA or dsDNA was added to a tube containing τ138 
(546-641) or τ138 (1-179) at a specific concentration (e.g. 500 µM). The tubes were incubated 
for 30 min at room temperature. 2 µL of native loading dye was added to each sample and the 
samples were loaded onto a native 4.5% acrylamide gel (4.5% acrylamide, 10% sucrose, 20 mM 
Tris HCl pH 8.0) which had been pre-run for 2 hours at 100 V. The gel was run at 120 V for 2 
hours in a Tris-glycine running buffer. After migration, the gel was dried and auto-
radiographed with X-ray film (Biomax, MR-film, Kodak).  
 
6.2.5 Cross-linking TFIIIC bound and unbound to tDNA 
Cross-linking reactions were performed as in Section 6.1.2. For TFIIIC bound to tDNA, the TFIIIC 
was first incubated with the 66 base-pair tDNAGlu oligonucleotide that had been shown to bind 
TFIIIC by EMSA. 30 μg (1 μg/μl or 2 μM) of TFIIIC was incubated with an excess (5 μM) of 
double-stranded tDNAGlu.  
 
6.3 Results – producing recombinant TFIIIC 
The protocols included here are based on the Handbook ‘Eukaryotic Expression Facility at 
EMBL Grenoble’ from Frederic Garzoni and Imre Berger, and on published protocols [159, 162]. 
 
6.3.1 Virus generation for Sf21 insect cell expression 
(i) Bacmid Generation 
2 µL of plasmid (pPBac τA or pKL τB) was transformed into electrically competent EMBacYFP 
cells. 900 µL of SOC media was added and the cells were incubated overnight at 37°C. This 
longer incubation before plating ensures higher success for the integration of the plasmid into 
the Tn7 sites in the Bacmid backbone. Cells were then plated out onto LB-Agar plates 
containing kanamycin (50 µg/mL), tetracycline (12 µg/mL), gentamycin (10 µg/mL), ampicillin 
(100 µg/mL), IPTG (1 mM) and BluOGal (100 µg/mL) in serial dilutions. Plates were incubated 
at 37°C for 36-48 hours so that there was sufficient time to make a clear distinction between 
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blue and white colonies. White colonies have successfully integrated the plasmid into the 
Bacmid DNA backbone. 4 white colonies and 1 blue colony were re-streaked onto plates and 
incubated overnight at 37°C as a control. 4 white colonies were then picked and inoculated in 2 
mL of LB medium containing antibiotics and incubated overnight at 37°C. The Bacmid DNA was 
isolated using the Qiaprep Spin miniprep kit (Qiagen) and stored at -20°C until required. 
(ii) V0 and V1 Virus Generation 
All steps are carried out in a cell-culture hood at 27°C.  
One well of a six-well plate was seeded with 3 mL of Sf21 cells at a density of 0.5 x 106 and 
allowed to settle for at least 30 min. Two Eppendorf tubes were prepared: one containing 10 
µL of Insectogene (Biontex) combined with 90 µL of Sf900 III SFM media (Invitrogen) and the 
second tube containing 2.5 µg Bacmid DNA in a total volume of 100 µL media. The two tubes 
were combined and left for 30 min to form virus particles. The supernatant from each well was 
removed, leaving a layer of Sf21 cells. 800 µL of media was added to each Bacmid DNA-
Insectogene tube and then mixed, before being pipetted onto the cells. For a control well, 2 
mL of media was added, in order to test for contamination from the cell stock. After 4 hours, 
the supernatant was removed and 2 mL of fresh media was added. V0 virus was harvested after 
60 hours (i.e. the supernatant was removed from the well and spun down to remove any 
remaining cell debris). The V0 virus was then added to 25 mL of Sf21 cells at a density of 0.5 x 
106. Cells were checked every 24 hours for cell proliferation arrest – i.e. when cells stop 
doubling. 72 hours after proliferation arrest (or when the YFP levels plateaued) cells were 
harvested by centrifugation at 800g for 10 min. V1 virus supernatant was removed and stored 
at 4°C.  
 
6.3.2 Expression and purification of τA 
6 L of Sf21 cells were infected with V1 virus at a dilution of 1 in 10000. When YFP/CFP levels 
had plateaued the cells were harvested at 800g for 20 min. Cell pellets were re-suspended in 
lysis buffer (25 mM Tris pH 7.5 (at 4°C), 150 mM  NaCl, 10 mM imidazole, 1 mM MgCl2, 
Complete EDTA-free protease inhibitor cocktail (Roche), DNaseI (Roche), 1 mM β-
mercaptoethanol) (100 mL per 2L cell pellet). For lysis, cells were subjected to two rounds of 
flash-freezing in liquid nitrogen, followed by thawing. The lysate was then centrifuged at 
20,000 rpm for 90 mins. The soluble fraction was circulated for at least 4 hours (or overnight) 
at 4°C on a TALON nickel affinity column (Clontech) which had been pre-equilibrated in lysis 
buffer. The column was washed with 20 column volumes of high salt buffer (25 mM Tris pH 7.5 
(at 4°C), 1 M NaCl, 10 mM imidazole, Complete EDTA-free protease inhibitor cocktail (Roche), 
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DNaseI (Roche), 1 mM β-mercaptoethanol), before being re-equilibrated in binding buffer (25 
mM Tris pH 7.5 (at 4°C), 150mM NaCl, 10 mM imidazole, Complete EDTA-free protease 
inhibitor cocktail (Roche), DNaseI (Roche), 1 mM β-mercaptoethanol). A step elution was 
performed using elution buffer (25 mM Tris pH 7.5 (at 4°C), 150 mM  NaCl, 250 mM imidazole, 
1 mM MgCl2, Complete EDTA-free protease inhibitor cocktail (Roche), DNaseI (Roche), 1 mM β-
mercaptoethanol). 3 mL fractions were collected and fractions which corresponded to a peak 
in absorbance were analysed by SDS-PAGE and pooled accordingly. The eluate was 
concentrated to 4mL for gel filtration. Gel filtration was carried out using a 120 mL Superose 6 
column (GE Healthcare) that had been pre-equilibrated in gel filtration buffer (20 mM Tris pH 
7.5 (at 4°C), 150 mM NaCl, 2 mM DTT). The protein was injected using a 5 mL loop. 3 mL 
fractions were collected and fractions which corresponded to a peak in absorbance were 
analysed by SDS-PAGE. 
 
6.3.3 Co-expression and purification of τA + τB (TFIIIC) 
V1 Virus of both pPBac τA and pKL τB were used to infect 500 mL of Sf21 cells at a dilution of 1 
in 5000. When YFP/CFP/mCherry levels had plateaued the cells were harvested at 800g for 20 
min. Cell pellet was re-suspended in 70 mL of lysis buffer buffer (10% glycerol, 50 mM Tris pH 
7.5 (at 4°C), 200 mM  NaCl, 2 mM CaCl2, Complete EDTA-free protease inhibitor cocktail 
(Roche), DNaseI (Roche), 2 mM β-mercaptoethanol). For lysis, cells were subjected to 
sonication (40% power, 90s – 10s on, 15 s off). The lysate was then centrifuged at 20,000 rpm 
for 90 mins. The soluble fraction was incubated with 100 µL CBP resin for 2 hours at 4°C. The 
resin was then applied to a 2 mL disposable column (ThermoScientific) and washed 
sequentially with 30 column volumes of binding buffer (W1) (50 mM Tris pH 7.5 (at 4°C), 200 
mM NaCl, 0.1 mM CaCl2, 2 mM β-mercaptoethanol), high salt buffer (50 mM Tris pH 7.5 (at 
4°C), 1 M  NaCl, 0.1 mM CaCl2, 2 mM β-mercaptoethanol) and then back to binding buffer 
(W2). See also Figure 4.7. The protein was eluted from the beads in 400 µL elution steps using 
elution buffer 1 (50 mM Tris pH 7.5 (at 4°C), 200 mM NaCl, 2 mM EGTA, 2 mM β-
mercaptoethanol) and then elution buffer 2 (50 mM Tris pH 7.5 (at 4°C), 200 mM  NaCl, 5 mM 
EGTA, 2 mM β-mercaptoethanol). The eluate was concentrated to 200 µL for analytical gel 
filtration. Gel filtration was carried out using a 24 mL Superose 6 10/300 column (GE 
Healthcare) that had been pre-equilibrated in gel filtration buffer (20 mM Tris pH 7.5 (at 4°C), 
150 mM NaCl, 2 mM DTT). The protein was injected using a 500 µL loop. 500 µL fractions were 
collected and fractions which corresponded to a peak in absorbance were analysed by SDS-
PAGE.  
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6.3.4 EMSA of τA 
EMSA experiments were performed as in Section 6.2.4, but instead using a 256 bp tDNAGlu 
which contained the same 66 base sequence as used in Section 6.2.4 but was flanked by 
additional sequence.  
 
6.4 X-ray crystallography  
As many of the experiments described in this thesis are centred on X-ray crystallography 
experiments, this section will briefly describe some relevant theoretical and practical 
background to this technique.  
In order to obtain atomic structures, one first requires protein crystals. This step is 
regarded as the major bottleneck in X-ray crystallography. If crystals are obtained, then they 
must produce interpretable diffraction patterns upon exposure to X-rays. These diffraction 
patterns contain recorded intensities in the forms of ‘spots’ or ‘reflections’ that represent the 
electron density in reciprocal space. However, in order to reconstruct electron density in real 
space, one still requires phase information (the position of electrons within the crystal), which 
is lost in the diffraction experiment. This ‘phase problem’ can be solved by molecular 
replacement or experimental phasing. Some aspects of the X-ray crystallography pipeline that 
are relevant for this thesis are discussed below.  
 
6.4.1 Preparing protein for crystallisation 
To begin crystallisation trials a protein purity of > 90% (as assessed by SDS-PAGE) is desired. 
Secondly, proteins should elute from a gel filtration column as a single, mono-disperse, peak. A 
highly pure, homogenous protein solution is desired for crystallisation, as this will increase the 
probability of protein molecules forming an ordered lattice. It is not possible to determine the 
optimal protein concentration for crystallisation a priori. When setting screens, I trialled two 
concentrations: the highest achievable, and then half of this. Although there are no fixed rules 
for which concentration to reach, it is usually optimal to test as high concentration as is 
reachable in order to increase the probability of the protein solution reaching super-saturation 
and for crystals to form.  
 
6.4.2 Setting up crystallisation experiments 
A number of sparse-matrix screenings (such as JCSG+, Wizard) were used during initial 
crystallisation trials. These 96-well screens contain a wide-range of crystallisation solutions 
that can be tested on a nanolitre scale using an automated pipetting robot. For each screen, 
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every crystallisation ‘drop’ required 100 nL of protein solution, which was mixed with 100 nL of 
crystallisation solution. Screens were usually stored at 20°C but trials at 4°C were also 
attempted in more challenging cases. If crystals were obtained (usually after 2-3 days in the 
experiments presented in this thesis) then a refinement screen was set up around the 
successful condition. For refinement, a 96-well plate was again used, with the initial condition 
screened by changing two variables. After an assessment of these results, manual screens 
were established. Here, 24-well screens were set up by hand, with 1 µL of protein solution 
mixed with 1 µL of the crystallisation solution. The setup used in all manual crystallisation trials 
within this thesis was the hanging-drop method.  
 
6.4.3 Preparing crystals for data collection 
To minimise radiation damage brought about by exposure to X-rays (especially at synchrotron 
sources), data collection was carried out at liquid nitrogen temperature. This meant that 
crystals had to be flash-frozen in liquid nitrogen after they were collected (or ‘fished’). Crystals 
therefore had to be ‘cryo-protected’, to ensure that water in the protein crystals did not form 
ice upon freezing, which can significantly affect the quality of the subsequent diffraction. Data 
collection of the highest resolution datasets obtained in this thesis were carried out at 
synchrotron X-ray sources, using the rotation method. Crystals were rotated in 0.1° steps 
whilst exposed to X-rays with resulting diffraction patterns recorded.  
 
6.4.4 Data processing pipeline  
The major steps involved in processing data and solving a structure in this thesis are 
summarised in Figure 6.1. All data processing of diffraction images in this thesis was carried 
out using the program XDS [144]. The program begins by indexing the reflections in the XDS 
step, integrating the recorded intensities and indicating to the user the probable space group 
which best describes the recorded positions of the reflections. This step was repeated by 
modifying the input file with the calculated unit cell parameters and including the space group 
details. The parameters are refined and the cycle is repeated until convergence. The data was 
scaled in XSCALE and statistics describing the quality of the data are reported. In this thesis, 
particular attention was paid to the values of Rmerge, which indicates the precision of data and 
whether the correct space group has been assigned. Resolution limits were determined at this 
step, with attention paid to the values of I/σI and CC1/2 [167] in the highest resolution shell. 
Ultimately, the correct cut-off can only be truly be determined based on the final values of 
Rwork/Rfree at the end of refinement, and many alternative cut-offs may need to be tested. In 
this thesis, the I/σI was cut at ~2 and CC1/2 at ~0.6 in the highest resolution shell. After scaling, 
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XDSCONV was used to convert the reflections to a necessary format for later processing and to 
generate a set of test reflections that were used to calculate Rfree values during refinement. 
Finally, the file name was changed to .mtz for downstream phasing steps. 
 
 
Figure 6.1 Data processing pipeline. The key steps in processing the diffraction data and 
phasing performed in this thesis. See main text for details of the various steps.  *At the XDS 
step, Friedel’s law must be set to either ‘TRUE’ or ‘FALSE’ in the input file. FALSE was selected if 
anomalous differences had been measured.  
 
With intensities determined, phases were then required in order to complete the 
Fourier equations and calculate the electron density. Details of the phasing techniques used 
are described in the relevant results sections. 
 
6.4.5 Model building, refinement and validation 
In this thesis, model building was carried out using the program Coot [146] and refinement was 
carried out using Phenix [147]. For molecular replacement, a model is already present with 
112 
 
which to modify based on the interpreted electron density difference map. In the case of 
experimental phasing, a model must be built de novo. For the sulphur-SAD experiment 
performed in this thesis, the AutoBuild [151] feature in Phenix was implemented in order to 
provide a starting model that could be further modified (aided by the high resolution of the 
final dataset). During refinement, several parameters or restraints were included in order to 
ensure that the model was not over-fitted to the data and to reduce bias. These parameters 
were selected based on the quality of the data. For example, for low-resolution data it was not 
always possible to interpret side-chain density. As a consequence, refining B-factors (for 
example) for each individual atom was not suitable, whereas with high resolution data this 
strategy was appropriate. Selecting other strategies and parameters is highly dependent on 
the quality of data and was varied depending on the stage of the refinement.  
In order to assess the progress of refinement, the Rwork and Rfree values were checked 
after each refinement cycle. Rwork is a measure of the fit between the data and the model and 
should decrease after each refinement cycle. However, this value will keep decreasing if the 
model is over-fitted and must be cross-validated with the Rfree value. The Rfree value is a more 
accurate measure of whether the model is actually improving and if the model agrees with the 
original data, this value is generated by cross-validating with a test set of reflections that were 
set aside by XDSCONV earlier in the pipeline. In this thesis, once the Rfree value had stabilised, 
the refinement was abandoned and stereochemistry and geometry was validated using 
MolProbity [168]. 
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 APPENDIX  7.
 
7.1 TAP-tag purification of TFIIIC 
The protocol for purifying TAP-tagged TFIIIC has been outlined in the Doctoral thesis of 
Nicholas Taylor and was based on the purification of RNA polymerase I [39]. A detailed 
protocol is provided here and is summarised in Figure 2.1.   
 
Day 1: Preparations 
- See Buffer tables 1 & 2 
- Prepare all buffers – but do not add inhibitors/reducing agents until Day 2 
- Check conductivity of all buffers 
- Prepare 0.1 M PMSF (870 mg in 50 mL ethanol) 
- Place bead beater (+ glass beads) in the cold room, along with blade homogeniser, 
tubes for TEV protease reaction, 250 mL measuring cylinder, 4 x 1 L beakers, 2 L bottle 
- Place frozen cell paste in the cold room in a bucket covered in foil 
 
Preparing the Heparin Column 
Pump wash 
Manual run at 0.3 MPa pressure limit with water  
Run Stored Method, System No. 20: Tubes A and 8 go into 5 L water. Tube B into ‘Hep Clean’ 
Buffer. Run method at least twice. 
 
Day 2: Cell lysis and applying lysate to heparin column 
- Keep track of wet weights/dry weights 
- Remember to add last minute additives to buffers (e.g. protease inhibitors, reducing 
agents) before using them 
- Wash cells with ‘Cell wash’ buffer (for 100g add 100 mL) and homogenise 
- Centrifuge for 7000 rpm, 10 min. This removes wet mass. Measure the dry pellet and 
re-suspend in an equal volume of ‘Lysis’ buffer (prepare more lysis buffer than 
required as more is needed for the re-lysis) 
- Homogenise with blade homogenizer 
- Fill ¾ of the lysis chamber with glass beads (250 ml), fill chamber to the top with 
resuspended cells (~200 ml) and add 100 mg Pefablock 
- Assemble the bead beater and cool the chamber with ice / ‘Cooling’ buffer 
- Beat 9 times for 45 s with 90 s pauses in-between 
- Filter beads through metallic mesh (pore size 0.3 mm). Put filtered lysate into JA-14 
tubes, recover beads and place back into lysis chamber 
- Centrifuge with JA-14, for 1 hour at 14,000 rpm 
- Recover and filter the supernatant – begin applying to heparin column 
- Re-suspend un-lysed cells and repeat lysis as before  
- Load lysate from second lysis on equilibrated heparin column (see below) 
- Wash column overnight with 1 L ‘Hep Bind’ at 2-4 ml/min until UV is almost zero 
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Equilibration of heparin column 
Wash AKTA pumps. A1, A8 & B tubes with buffers ‘Hep A’, ‘ Hep bind’ & ‘Hep B’ respectively 
Manual run with 100% B, 50mL, then 0% B 50mL – ensure you are on WASTE 
Return to LOAD - equilibrate with 1 L Hep ‘Bind’ (A8 tube), until conductivity is flat 
 
Day 3:  Heparin elution and IgG binding steps 
- Equilibrate column in ‘Hep A’ Buffer 
- Elute with gradient 0-100%  ‘Hep B’ for 500 ml at 2-4 ml/min, collecting 1 fraction of 
~900 ml. The dead volume is about 200 mL 
 
Bead preparation for IgG binding 
Wash IgG beads (5 mL from 10 mL slurry) with H2O to remove ethanol (when washing always 
use 1 column volume) 
Then wash in the following order: 0.5 M Tris (pH 7.4), Acetic acid/NaOH (pH 3.4), 0.5M Tris (pH 
7.4), Acetic acid/NaOH (pH 3.4), 0.5 M Tris (pH 7.4) 
To make Acetic Acid/NaOH pH 3.4 (500 mL): fill up with H2O to 479 mL Acetic acid: 14.3 mL 
NaOH: 6.25 mL 
 
- Heparin eluate must be diluted with ‘Hep A’ buffer to reduce salt concentration for 
bead binding. Add a volume equivalent to the length of the peak from when B is at 
100% to end of elution peak (about 500 mL) 
- Add IgG resin to the heparin elution & incubate overnight at 4 °C with mild shaking  
 
Day 4:  TEV protease cleavage 
- Pass incubated eluate through a yellow column, collecting the flow-through 
- Wash with 200 ml ‘IgG bind’ buffer, re-suspend beads with 20 ml ‘IgG bind’ buffer and 
transfer to 2 clean tubes. 
- Add 1 mL of TEV protease (EMBL protein expression and purification facility) to each 
tube.  
- Top-up tubes with ‘IgG bind’ buffer (each tube holds approx. 15 mL) 
- Incubate overnight on rotating wheel 
- Clean MonoQ column in preparation for Day 5: 20 column volumes H2O, 0.5 M Tris, 
water, 0.5 M NaOH, H2O  
 
Day 5:  IgG ‘elution’ / MonoQ / concentration 
- Add tube contents to yellow column, and collect FT! 
- Pass 4x ‘IgG elution’ buffer in 5 mL steps through beads  
- Add ‘IgG elution’ buffer to a final volume of 150 mL 
- MonoQ preparation (use 10/100 column – 8 mL): wash column with H2O, ‘MonoQ A’, 
‘MonoQ B’, ‘MonoQ A’ 
- Inject IgG eluate with the 50 mL superloop – collect fractions immediately 
- Elute with a 350 mL gradient against ‘MonoQ B’   
- Collect 1 mL fractions 
- TFIIIC elutes at ~ 18% B, ~ 36 mS/cm 
 
Concentrate TFIIIC on a 30 kDa cutoff spinning concentrator (5mL) 
Analyse fractions by 10-12% SDS-PAGE 
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Buffer Table 1 : Lysis & Heparin 
Stocks Cell wash 
(2 L) 
Lysis 
(2 L) 
Cooling 
(4 L) 
Hep clean 
(5 L) 
Hep bind 
(2.5 L) 
Hep A 
(2 L) 
Hep B 
(2 L) 
1 M Tris pH 8 100 ml 500 ml - - 125 ml 100 
ml 
100 ml 
glycerol - 800 ml - - 1100 ml - - 
Ammonium 
sulphate 
52.86 g 52.86 g - - 66.08 g 52.86 
g 
264.28 
g 
0.5 M EDTA - 4 ml - - 5 ml 2 ml 2 ml 
5M NaCl - - 1200 g 585 g - - - 
β-EtSH - 96μl / 
100 mL 
- - 0.7 ml 150 ml 150 ml 
‘Complete’ 
Tablets* 
- 1 / 25 
ml 
- - - - - 
Pefablock - 1 
mg/ml 
- -    
0.1 M PMSF - - - - 10 ml 10 ml 10 ml 
DTT - - - - - - - 
Conductivity 
(ms/cm) 
- 12.23 - - 8.28 38.2 138.4 
* (- EDTA) (Roche) Pre-dissolve in Tris 
Ingredients in shaded boxes should be added on the day that the buffer is used 
 
Buffer Table 2 : IgG and MonoQ 
Stocks IgG bind 
(2 L) 
IgG elution 
(2 L) 
MonoQ A 
(4 L) 
MonoQ B 
(5 L) 
1 M Tris pH 8 25 ml 25 ml 40 ml 40 ml 
glycerol 100 ml - - - 
Ammonium 
sulphate 
6.61 g 2.112g - - 
0.5 M EDTA 500 ml 500 ml 1 ml 1 ml 
5M NaCl - - 20 ml 200 ml 
β-EtSH 75 ml 75 ml - - 
‘Complete’ 
Tablets* 
- - - - 
Pefablock - - - - 
0.1 M PMSF 0.1mg/ml 0.1mg/ml 0.1mg/ml 0.1mg/ml 
DTT - - 1.54g 1.54g 
Conductivity 
(ms/cm) 
12.76 10.7 14.16 90.4 
* (- EDTA) (Roche) Pre-dissolve in Tris 
Ingredients in shaded boxes should be added on the day that the buffer is used 
  
116 
 
7.2 Tables of cross-linked peptides 
 
Appendix Table B1 – TFIIIC inter cross-links without tDNA 
Peptide* Prot. 1 Prot. 2 Lys. 1 Lys. 2 ld-score** 
MLTNLDSKGNLSSR-NMKSSSPGSSLGQK τ60 τ91 124 142 46.39 
ISASTKDLSK-DSIKSLK τ138 τ95 896 138 43.28 
ISASTKDLSK-SLKDSNK τ138 τ95 896 141 40.11 
KSTSVNVSDGK-KTGQLAR τ138 τ131 698 242 39.36 
MLTNLDSKGNLSSR-NSTKNMK τ60 τ91 124 139 39.35 
KTAGLLSPTEENETTNAGQSK-VKEAFK τ55 τ95 359 66 38.54 
ASDDAISKK-KTGQLAR τ138 τ131 697 242 38.51 
DHTGDKEEVQSEKIYR-VKEAFK τ55 τ95 419 66 38.33 
NSSATQKSLR-GFDELGKSR τ91 τ138 598 433 37.53 
FKNSTFDSLLAAEK-IKASDDAISK τ131 τ138 412 689 36.91 
MLTNLDSKGNLSSR-NTVQKLR τ60 τ91 124 130 35.78 
EKSYNIPIDIR-IKASDDAISK τ131 τ138 426 689 35.28 
DHTGDKEEVQSEK-AIKMCGGIEK τ55 τ95 412 57 34.50 
DHTGDKEEVQSEK-VKEAFK τ55 τ95 412 66 30.13 
KVLVVSPK-YEKMKK τ138 τ131 240 636 28.79 
KLLSSPIVK-EVYNPNKK τ95 τ131 395 871 28.67 
EKSYNIPIDIR-KSTSVNVSDGK τ131 τ138 426 698 28.39 
FKNSTFDSLLAAEK-ASDDAISKK τ131 τ138 412 697 28.37 
SSSPGSSLGQKGRPIR-MLTNLDSKGNLSSR τ91 τ60 153 124 28.36 
EKSYNIPIDIR-ASDDAISKK τ131 τ138 426 697 28.33 
DHTGDKEEVQSEKIYR-VTMPKGTLSK τ55 τ95 419 123 27.86 
DESVILKVTMPK-SKNGIR τ95 τ138 118 200 27.62 
LDPKTAETMK-YHKIRK τ95 τ131 631 947 27.25 
LFTAQNFQKLTNAEDEISVPK-WDYSIKDDKYR τ138 τ91 414 610 27.09 
RIKLEQHVSTAQEPK-NSSATQKSLR τ138 τ91 509 598 26.67 
KTGQLAR-KVSAGR τ131 τ138 242 715 26.17 
TTVVVENTKEDK-KIDAKYK τ138 τ131 729 349 26.15 
MSLNENGDKIR-DSNKLR τ55 τ95 196 145 26.08 
AILKVMNTIGGVAYLR-KTGQLAR τ138 τ131 561 242 25.72 
IYGLNKEK-IPPNSKK τ91 τ138 178 478 25.69 
LLSSPIVKK-EVYNPNKK τ95 τ131 403 871 25.54 
SLYTDLEKQEADYNLGR-SVKIPSTDFQLPPPPK τ131 τ95 958 219 25.40 
ITAKVVDK-KTYTRK τ131 τ138 627 885 25.24 
 
Appendix Table B2 – TFIIIC intra cross-links without tDNA 
Peptide* Prot. 1 Prot. 2 Lys. 1 Lys. 2 ld-score** 
ITGKEFQR-NPAIKIR τ138 τ138 362 252 45.76 
KVLVVSPK-NPAIKIR τ138 τ138 240 252 41.79 
LLKDLSSAR-NSTKNMK τ91 τ91 161 139 41.38 
IYGLNKEK-LLLLAKVK τ91 τ91 178 186 40.74 
LLHGIKNSSATQK-LLKDLSSAR τ91 τ91 591 161 40.34 
KSTSVNVSDGK-IKASDDAISK τ138 τ138 698 689 39.79 
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ITAKVVDKYEK-KHQVDETLHR τ131 τ131 627 567 39.12 
SGLKGISTMDVVNR-NPAIKIR τ138 τ138 348 252 39.12 
IKASDDAISK-KVSAGR τ138 τ138 689 715 39.10 
NMKSSSPGSSLGQK-LLKDLSSAR τ91 τ91 142 161 38.13 
AFTKSSEYYLESVDK-ITGKEFQR τ138 τ138 370 362 38.05 
GDVDLMVESEKLGAR-GKVVNFGGFSAR- τ138 τ138 607 538 37.99 
LLKDLSSAR-LLLLAKVK τ91 τ91 161 186 37.61 
ITGKEFQR-CVKYVK τ138 τ138 362 257 37.52 
AKIDAHGINITCTK-WDYSIKDDKYR τ91 τ91 634 610 37.26 
NEIEALKNVGNESIDNVIMDMAK-VPLGKPFSR τ138 τ138 930 1073 37.18 
NMKSSSPGSSLGQK-LLHGIKNSSATQK- τ91 τ91 142 591 36.96 
DINCNSKNLFHVK-LLKDLLVDRK τ60 τ60 53 5 36.70 
TTVVVENTKEDK-KVSAGR τ138 τ138 729 715 36.63 
ISASTKDLSK-KTYTRK τ138 τ138 896 885 36.61 
LLKDLSSAR-IYGLNKEK τ91 τ91 161 178 36.47 
DLSKSQSDDYIR-VPLGKPFSR τ138 τ138 900 1073 36.04 
TAETMKSELK-IAKLDPK τ95 τ95 637 627 35.94 
GTLSKNNNSVK-DSIKSLK τ95 τ95 128 138 35.70 
SAEDSPSSNGGTVVKGK-GDVDLMVESEKLGAR τ138 τ138 536 607 35.69 
IPSLELPLNVSTKHSSIQK-VTMPKGTLSK τ95 τ95 48 123 35.51 
LLKDLSSAR-NTVQKLR τ91 τ91 161 130 35.27 
SSNDTSDISSKPLLEDSKFR-KHQVDETLHR τ131 τ131 599 567 34.86 
NSSATQKSLR-NTVQKLR τ91 τ91 598 130 34.18 
KSTSVNVSDGKIK-KVSAGR τ138 τ138 708 715 33.99 
CYKEIESYETAK-KFVGILR τ131 τ131 513 678 33.83 
CYKEIESYETAK-TTDVFKPLAR τ131 τ131 513 506 33.47 
IYDFEGKKK-CVKYVK τ138 τ138 400 257 33.40 
ITKLFPNNSLDNLK-TTVVVENTKEDK τ138 τ138 767 729 33.32 
NSTKNMK-NTVQKLR τ91 τ91 139 130 33.11 
STSVNVSDGKIK-ASDDAISKK τ138 τ138 708 697 32.98 
IKASDDAISKK-EKDSKK τ138 τ138 689 642 32.85 
SSNDTSDISSKPLLEDSKFR-KHQVDETLHR τ131 τ131 592 567 32.74 
NMKSSSPGSSLGQK-DIATTKTTVSR τ91 τ91 142 503 32.68 
SSSPGSSLGQKGRPIR-NSTKNMK τ138 τ138 153 139 32.57 
SSSPGSSLGQKGRPIR-NSSATQKSLR τ91 τ91 153 598 32.49 
KHQVDETLHR-VVDKYEK τ131 τ131 567 631 32.39 
KSTSVNVSDGK-KVSAGR τ138 τ138 698 715 32.31 
KFNTELDFQIER-VVDKYEK τ131 τ131 688 631 32.27 
SSSPGSSLGQKGRPIR-NTVQKLR τ91 τ91 153 130 32.26 
SSNDTSDISSKPLLEDSKFR-KRTPYDAER τ131 τ131 599 607 32.09 
NMKSSSPGSSLGQK-RNTVQKLR τ91 τ91 142 130 32.04 
VKEGFETSVFDFPFK-IYGLNKEK τ91 τ91 188 178 32.03 
YAKDINCNSK-ICPVSKQR τ60 τ60 46 549 32.01 
EASNFKVK-GKSYGR τ131 τ131 102 113 31.85 
TDLKTLNEDNFVALNNTVR-RSKNGIR τ138 τ138 439 200 31.73 
EFEDWKNNLTWAR-KITDLK τ60 τ60 18 228 31.67 
AFTKSSEYYLESVDK-CVKYVK τ138 τ138 370 257 31.40 
SSSPGSSLGQKGRPIR-DIATTKTTVSR τ91 τ91 153 503 31.33 
RLLHGIKNSSATQK-NSTKNMK τ91 τ91 591 139 31.16 
RLLHGIKNSSATQK-NTVQKLR τ91 τ91 591 130 30.94 
IKASDDAISKK-YILKEK τ138 τ138 689 637 30.94 
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LSKLAEGDSVFEGPLMEER-ITAKVVDKYEK τ131 τ131 702 627 30.80 
NSTNASVAGNISNPKR-IKLEQHVSTAQEPK τ138 τ138 506 509 30.78 
IPSLELPLNVSTKHSSIQK-AIKMCGGIEK τ95 τ95 48 57 30.59 
RQVKNSTNASVAGNISNPK-RIKLEQHVSTAQEPK τ138 τ138 491 509 30.26 
ISNEKSSNDTSDISSKPLLEDSK-KHQVDETLHR τ131 τ131 581 567 30.18 
NSTNASVAGNISNPKR-GKVVNFGGFSAR τ138 τ138 506 538 29.71 
AFTKSSEYYLESVDK-GHVVKQLK τ138 τ138 370 165 29.51 
DNKMLTNLDSK-VIDIKR τ60 τ60 116 556 29.31 
IPPNSKK-TPNKNK τ138 τ138 478 483 29.28 
TTVVVENTKEDKTVYHAGTK-KVSAGR τ138 τ138 732 715 29.28 
EIKRPLFLYK-KFTLVR τ138 τ138 839 854 29.26 
SAEDSPSSNGGTVVKGK-AILKVMNTIGGVAYLR τ138 τ138 536 561 29.22 
DIATTKTTVSR-NTVQKLR τ91 τ91 503 130 29.12 
AFTKSSEYYLESVDK-QKENTGGYR τ138 τ138 370 383 28.95 
LSKLAEGDSVFEGPLMEER-VVDKYEK τ131 τ131 702 631 28.90 
ITKLFPNNSLDNLK-KVSAGR τ138 τ138 767 715 28.82 
LFTAQNFQKLTNAEDEISVPK-QKENTGGYR τ138 τ138 414 383 28.40 
NMKSSSPGSSLGQK-NSSATQKSLR τ91 τ91 142 598 27.99 
KFELNSGLNEAK-VVDKYEK τ131 τ131 637 631 27.81 
NEIEALKNVGNESIDNVIMDMAK-DLSKSQSDDYIR τ138 τ138 930 900 27.70 
ASDDAISKK-KVSAGR τ138 τ138 697 715 27.63 
SSSPGSSLGQKGRPIR-LLKDLSSAR τ91 τ91 153 161 27.34 
SGEKGINTMDLAQVTGQDPR-KINHLLTSSQLIYK τ138 τ138 123 147 27.31 
NVPKPPPLVFESDTPGGIDSR-KLLSSPIVKK τ95 τ95 408 403 27.29 
ANPFAKKK-KNGVTEVK τ95 τ95 251 254 27.08 
EASNFKVK-KNDKGK τ131 τ131 102 108 26.84 
GTLSKNNNSVK-SLKDSNK τ95 τ95 128 141 26.59 
KSTSVNVSDGK-EKDSKK τ138 τ138 698 639 26.34 
GTLSKNNNSVK-DSNKLR τ95 τ95 128 145 26.15 
NMKSSSPGSSLGQK-IYGLNKEK τ91 τ91 142 178 26.09 
QKENTGGYR-IPPNSKK τ138 τ138 383 478 25.69 
 
Appendix Table B3 – TFIIIC inter cross-links with tDNA 
Peptide* Prot. 1 Prot. 2 Lys. 1 Lys. 2 ld-score** 
MLTNLDSKGNLSSR-NTVQKLR τ60 τ91 124 130 42.62 
MLTNLDSKGNLSSR-NMKSSSPGSSLGQK τ60 τ91 124 142 40.62 
ISASTKDLSK-DSIKSLK τ138 τ95 896 138 39.75 
MLTNLDSKGNLSSR-NSTKNMK τ60 τ91 124 139 39.49 
NSTNASVAGNISNPKR-MLTNLDSKGNLSSR τ138 τ60 506 124 38.69 
KIIFLPTVGEDAIQR-GKSYGR τ138 τ131 619 113 36.55 
KTAGLLSPTEENETTNAGQSK-VKEAFK τ55 τ95 359 66 35.82 
SGSCSLDKYEILKK-GKSYGR τ55 τ131 211 113 35.04 
EKSYNIPIDIR-KSTSVNVSDGK τ131 τ138 426 698 34.80 
KLLSSPIVKK-EVYNPNKK τ95 τ131 395 871 34.77 
KISASTKDLSK-SLKDSNK τ138 τ95 896 141 33.85 
EKSYNIPIDIR-ASDDAISKK τ131 τ138 426 697 33.80 
FKNSTFDSLLAAEK-ASDDAISKK τ131 τ138 412 697 33.77 
DHTGDKEEVQSEKIYR-VKEAFK τ55 τ95 419 66 32.98 
DHTGDKEEVQSEK-AIKMCGGIEK τ55 τ95 412 57 31.98 
119 
 
KSTSVNVSDGK-KTGQLAR τ138 τ131 698 242 30.83 
KTAGLLSPTEENETTNAGQSK-AIKMCGGIEK- τ55 τ95 359 57 30.05 
MSLNENGDKIR-DSNKLR τ55 τ95 196 145 29.03 
EKSYNIPIDIR-KVSAGR τ131 τ138 426 715 28.93 
SLYTDLEKQEADYNLGR-SVKIPSTDFQLPPPPK τ131 τ95 958 219 28.70 
ASDDAISKK-KTGQLAR τ138 τ131 697 242 27.44 
TTVVVENTKEDK-KIDAKYK τ138 τ131 729 349 27.41 
FKNSTFDSLLAAEK-LLSSPIVKK τ131 τ95 412 403 27.12 
STSVNVSDGKIK-EKSYNIPIDIR τ138 τ131 708 426 26.64 
KTGQLAR-EKDSKK τ131 τ138 242 642 25.82 
KTGQLAR-KVSAGR τ131 τ138 242 715 25.04 
 
Appendix Table B4 – TFIIIC intra cross-links with tDNA 
Peptide* Prot. 1 Prot. 2 Lys. 1 Lys. 2 ld-score** 
NMKSSSPGSSLGQK-IYGLNKEK τ91 τ91 142 178 44.25 
NMKSSSPGSSLGQK-LLKDLSSAR τ91 τ91 142 161 43.22 
GTLSKNNNSVKDSIK-DSNKLR τ95 τ95 128 145 41.40 
KNSENTPEFYFESSIR-DNKMLTNLDSK τ60 τ60 160 116 41.27 
KVLVVSPK-NPAIKIR τ138 τ138 240 252 41.23 
SGLKGISTMDVVNR-NPAIKIR τ138 τ138 348 252 40.52 
GDVDLMVESEKLGAR-GKVVNFGGFSAR τ138 τ138 607 538 40.42 
LLHGIKNSSATQK-LLKDLSSAR τ91 τ91 591 161 39.97 
LLKDLSSAR-IYGLNKEK τ91 τ91 161 178 39.91 
ITGKEFQR-CVKYVK τ138 τ138 362 257 39.80 
NMKSSSPGSSLGQK-DIATTKTTVSR τ91 τ91 142 503 39.66 
GTLSKNNNSVK-DSIKSLK τ95 τ95 128 138 39.23 
ISASTKDLSK-KTYTRK τ138 τ138 896 885 38.70 
KSTSVNVSDGK-IKASDDAISK τ138 τ138 698 689 38.35 
ASDDAISKK-KVSAGR τ138 τ138 697 715 38.33 
DIATTKTTVSR-NTVQKLR τ91 τ91 503 130 38.15 
IYGLNKEK-LLLLAKVK τ91 τ91 178 186 38.13 
GTLSKNNNSVK-SLKDSNK τ95 τ95 128 141 38.11 
NSTKNMK-NTVQKLR τ91 τ91 139 130 38.10 
NMKSSSPGSSLGQK-NTVQKLR τ91 τ91 142 130 38.01 
DINCNSKNLFHVK-LLKDLLVDRK τ60 τ60 53 5 37.14 
TAETMKSELK-IAKLDPK τ95 τ95 637 627 36.38 
NSTNASVAGNISNPKR-KIIFLPTVGEDAIQR τ138 τ138 506 619 35.91 
IKASDDAISK-KVSAGR τ138 τ138 689 715 35.84 
LLHGIKNSSATQK-NSTKNMK τ91 τ91 591 139 35.43 
VKEGFETSVFDFPFK-IYGLNKEK τ91 τ91 188 178 35.37 
KFELNSGLNEAK-VVDKYEK τ131 τ131 637 631 35.16 
KIIFLPTVGEDAIQR-YILKEK τ138 τ138 619 637 35.10 
AFTKSSEYYLESVDK-CVKYVK τ138 τ138 370 257 34.92 
KFNTELDFQIER-VVDKYEK τ131 τ131 688 631 34.86 
TTVVVENTKEDK-KVSAGR τ138 τ138 729 715 34.78 
DLSKSQSDDYIR-KISASTK τ138 τ138 900 890 34.68 
SGLKGISTMDVVNR-VLVVSPKNPAIK τ138 τ138 348 247 34.65 
YAKDINCNSK-ICPVSKQR τ60 τ60 46 549 34.63 
KIIFLPTVGEDAIQR-KVSAGR τ138 τ138 619 715 34.61 
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CYKEIESYETAK-TTDVFKPLAR τ131 τ131 513 506 34.46 
LLKDLSSAR-NSTKNMK τ91 τ91 161 139 34.18 
STSVNVSDGKIK-ASDDAISKK τ138 τ138 708 697 34.14 
KSTSVNVSDGK-KVSAGR τ138 τ138 698 715 33.99 
AFTKSSEYYLESVDK-ITGKEFQR τ138 τ138 370 362 33.94 
IYGLNKEK-NSTKNMK τ91 τ91 178 139 33.84 
ITKLFPNNSLDNLK-TTVVVENTKEDK τ138 τ138 767 729 33.81 
SSNDTSDISSKPLLEDSK-KHQVDETLHR τ131 τ131 592 567 33.40 
IKASDDAISK-YILKEK τ138 τ138 689 637 33.27 
IPSLELPLNVSTKHSSIQK-VTMPKGTLSK τ95 τ95 48 123 33.08 
STSVNVSDGKIK-KVSAGR τ138 τ138 708 715 32.98 
DIATTKTTVSR-NSTKNMK τ91 τ91 503 139 32.74 
ITGKEFQR-NPAIKIR τ138 τ138 362 252 32.66 
LSMVGFPLLYKYK-ANPFAKK τ95 τ95 243 251 32.50 
LSKLAEGDSVFEGPLMEER-ITAKVVDKYEK τ131 τ131 702 627 32.38 
KIIFLPTVGEDAIQR-YMGSTTTLDKK τ138 τ138 619 592 32.27 
LLKDLSSAR-LLLLAKVK τ91 τ91 161 186 32.21 
QVKNSTNASVAGNISNPK-TPNKNK τ138 τ138 491 483 32.15 
SGEKGINTMDLAQVTGQDPR-QLKLKK τ138 τ138 123 170 31.74 
IYDFEGKKK-ITGKEFQR τ138 τ138 401 362 31.60 
STSVNVSDGKIK-TTVVVENTKEDK τ138 τ138 708 729 31.51 
IYDFEGKKK-ITGKEFQR τ138 τ138 400 362 30.59 
AFTKSSEYYLESVDK-QKENTGGYR τ138 τ138 370 383 30.51 
NSTNASVAGNISNPKR-IPPNSKK τ138 τ138 506 478 30.43 
NSSATQKSLR-LKKNSTK τ91 τ91 598 134 30.22 
IYGLNKEK-NTVQKLR τ91 τ91 178 130 29.81 
IPPNSKK-TPNKNK τ138 τ138 478 483 29.65 
EASNFKVK-GKSYGR τ131 τ131 102 113 27.62 
GTYIKNYQLFVHDLSDK-ANPFAKK τ95 τ95 266 251 27.42 
 
* Cross-linked lysines are underlined and in bold 
** All values are listed in descending order of Id Score, only cross-links with an ld score >25 
were selected for analysis 
Prot. = Protein / Lys. = Lysine 
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